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Abstract
Association of changes in norepinephrine and serotonin transporter
expression with the long-term behavioral effects of antidepressant drugs
Zaorui Zhao
The relationship between the ability of repeated antidepressant treatment to cause
down-regulation of the norepinephrine and serotonin transporters (NET, SERT) and
produce antidepressant-like effects on behavior was determined.  Treatment of rats with
15 mg/kg/day desipramine reduced NET expression, measured by 3H-nisoxetine binding
and SDS-PAGE/immunoblotting, in cerebral cortex and hippocampus and reduced the
time of immobility in the forced-swim test.  The antidepressant-like effect on forced-
swim behavior was evident two days following discontinuation of desipramine treatment
when plasma and brain levels of desipramine and its major metabolite desmethyl-
desipramine were not detectable.  Reduced NET expression resulted in decreased
norepinephrine (NE) uptake, measured in vitro, and increased noradrenergic
neurotransmission, measured in vivo using microdialysis.  Fourteen-day treatment of rats
with 20 mg/kg/day protriptyline or 7.5 mg/kg/day sertraline reduced NET and SERT
expression, measured by 3H-nisoxetine/3H-citalopram binding and SDS-
PAGE/immunoblotting, in cerebral cortex and hippocampus and reduced the time of
immobility in the forced-swim test.  Six-week, but not 2-week, treatment with 20
mg/kg/day reboxetine caused down-regulation of NET and an antidepressant-like effect
in the forced-swim test.  Antidepressant-induced NET and SERT down-regulation was
not due to the reduction of gene transcription, as determined using quantitative, real-time
RT-PCR.
Since studies using cell cultures have revealed a role of protein kinase C (PKC) in
NET regulation, experiments were carried out to assess the importance of this mechanism
in brain tissues and determine its role in the mediation of antidepressant-like effects on
behavior.  It was found that the PKC activators β-PMA and bryostatin-1 reduced NE
uptake in cerebrocortical slices; this was due to decreased Vmax and unchanged Km
values.  Further, bilaterally intracerebroventricular (ICV) administration of β-PMA
produced a significant antidepressant-like effect on forced-swim behavior, which was
reversed by co-administration of 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7), a
PKC inhibitor.
Overall, antidepressant-induced changes in NET/SERT expression paralleled those in
the antidepressant-like effects on behavior.  The antidepressant-like effects of
desipramine and sertraline were blocked by inhibition of catecholamine synthesis with
alpha-methyl-p-tyrosine (AMPT) and inhibition of serotonin (5-HT) synthesis with para-
chlorophenylalanine (PCPA), respectively, suggesting that increased noradrenergic or
serotonergic neurotransmission is an important mechanism underlying antidepressant
activity.  In addition, the results, which are consistent with clinical data in terms of time-
course respone, suggest an important role of NET and SERT regulation in the long-term
behavioral effects of antidepressant drugs and that enhanced noradrenergic or
serotonergic neurotransmission is necessary, but not sufficient, for its antidepressant
actions.  Understanding the mechanisms underlying NET and SERT regulation in vivo
may suggest novel pharmacological targets for treating depression.  Future studies may
focus on identifying the role of PKC signaling in NET regulatio, given thaht this
signaling pathway appears to be an important mediator contributing to the long-term
behavioral effects of antidepressant treatment.
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CHAPTER 1
INTRODUCTION
2
LITERATURE REVIEW
1.1 Depression and its treatment
The mood disorders, primarily major depressive-anxiety and bipolar disorder, are
among the most prevalent forms of mental illness and are associated with dramatic
reductions in work capacity, overall health, and longevity (Thase and Denko, 2008;
Nestler et al., 2002).  Severe depression affects 2% - 5% of the U.S. population during a
single year; 20% of the population suffers from milder depression.  Mood disorders are
life threatening due to the high risk of suicide (Blazer, 2000; Akiskal, 2000).
Diagnosis of depression is based on symptomatic criteria in the Diagnostic and
Statistical Manual (DSM-IV, 2000) and its severity can be quantified using the Hamilton
depression rating scale (HAM-D) (Hamilton, 1960; Hamilton, 1967).  These symptomatic
criteria consist of depressed mood, irritability, low self-esteem, feelings of hopelessness,
worthlessness, and guilt, decreased ability to concentrate and think, decreased or
increased appetite, weight loss or weight gain, insomnia or hypersomnia, low energy,
fatigue and increased agitation.
Roughly 40%-50% of the risk of depression is genetic (Sanders et al., 1999; Fava and
Kendler, 2000), which makes depression a highly heritable disorder.  However, the
difficulty in finding specific genes implicated in depression is likely due to the fact that it
is a complex psychiatric disease with many genes involved (Burmeister, 1999).  Thus,
any single gene might produce a relatively small effect and therefore its role would be
difficult to detect experimentally.  In addition, nongenetic factors are also the causes of
depression.  The nongenetic etiology of depression consists of stress, emotional trauma,
viral infections, and random processes during brain development (Akiskal, 2000; Fava
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and Kendler, 2000).  Episodes of depression usually occur in the context of stress, but
stress is not sufficient to produce depression; i.e., not all people developing depression do
so after a serious stress experience.  It appears that depression is caused by interactions
between genetic predisposition and environmental factors.
The finding that depletion of brain monoamines by reserpine, which blocks vesicular
monoamine storages, induces despression-like symptoms, led to speculation that NE is
deficient in depression.  However, only a small number of individuals given reserpine
actually develop depression.  Further, depletion of monoamines by AMPT in normal
subjects does not induce significant changes in mood (Salomon et al., 1997).  Acute
treatment with antidepressants that block the NET does not produce remission of
symptoms of depression, even though the extraceullar NE level is elevated.  Taken
together, these findings argue against a simple role for NE in the pathology of depression
and indicate that monoamine deficiency itself is insufficient to cause symptoms of
depression (Miller et al., 1996b).  However, rapid depletion of NE by AMPT results in
depression relapse in the patients who have successfully responded to desipramine, an
antidepressant that blocks the NET.  A specific role for noradrenergic neurotransmission
is suggested by the finding that NE-deficient mice fail to respond to the behavioral effects
of the NE reuptake inhibitor desipramine.  Restoration of NE by l-threo-3,4-
dihydroxyphenylserine reinstates the behavioral effects of desipramine in these mice
(Cryan et al., 2004).
Most of the NE in the brain arises from the cell bodies in the locus ceruleus (LC).
The projections of these neurons are diffuse and overlap, nerve terminals in a wide range
of brain regions including prefrontal and cingulate cortex, hippocampus, striatum,
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amygdala, and thalamus (Drevets, 2001; Liotti and Mayberg, 2001).  These brain regions
play an important role in the mediation of cognition, depression, and emotional memory.
The function of these brain regions suggests the aspects of depression to which they may
contribute.  Neocortex and hippocampus might mediate the cognitive aspects of
depression, e.g. impairment of memory, feeling of worthless, guilt and suicidality. The
striatum and amygdala are believed to relate to emotional memory, anxiety, and reduced
motivation, symptoms observed in depressed patients. The role of the hypothalamus is
speculated to involve sleep, activity, appetite, energy and a loss of interest in sex in
depression (Nestler et al., 2002).
The role of 5-HT in the mediation of depression parallels, in many ways, that of NE.
Clinically, in untreated patients, it has been reported that reducing serotonergic activity
with tryptophan depletion does not produce symptoms of depression in normal subjects
(Miller et al., 1996b).  However, inhibition of 5-HT synthesis with PCPA or a
tryptophan-free amino-acid drink reverses the antidepressant effects of selective
serotonin reuptake inhibitors (SSRIs) in depressed subjects (Miller et al., 1996a; Salomon
et al., 1993).
The majority of brain serotonergic innervation originates in the dorsal and median
raphe nuclei.  The serotonergic neurons in these two nuclei project to almost every region
of the brain, including cortical and subcortical areas.  Neurons in the dorsal raphe project
mostly to striatum and substantia nigra, while those in the median raphe project to septum
and hippocampus.  Serotonergic terminals densely innervate the limbic system.
The majority of depressed patients show improvement with antidepressant
medications or electroconvulsive therapy  (ECT).  Specific antidepressant medications
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were first developed in the 1950s, with the discovery of two classes of agents, the
monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants. MAOI, e.g.,
phenelzine and iproniazid, elevate neurotransmission by inhibition of monoamine
oxidase, a major catabolic enzyme involved in the degradation of monoamine
neurotransmitters.  Tricyclic antidepressants, e.g. imipramine and desipramine, inhibit the
reuptake of NE or 5-HT by blocking the transporters (NET, SERT).  Progress in
antidepressant development advanced notably with the SSRIs, e.g., fluoxetine, sertraline,
paroxetine; these result in fewer serious side effects and have less overdose hazard
(Murphy et al., 2000).  Subsequently, a selective norepinephrine reuptake inhibitors
(NRIs) antidepressant was developed, i.e., reboxetine.  The dual norepinephrine-serotonin
reuptake inhibitors (NSRIs), venlafaxine and duloxetine, were then developed.  Studies in
inpatients and outpatients comparing venlafaxine with SSRIs e.g, fluoxetine, sertraline,
and paroxetine reveal higher response or remission rates with the dual inhibitor
venlafaxine (Clerc et al., 1994; Dierick et al., 1996; Ballus et al., 2000; Poirier and Boyer,
1999; Mehtonen et al., 2000) although other studies have not demonstrated superior
efficacy (Thase et al., 2006).  α -2 Adrenergic receptor antagonists, e.g., idazoxan,
yohimbine, and antipamizole, have been shown to exhibit some antidepressant-like
activity, and increase neuronal firing and synaptic NE levels in conjunction with NRIs
antidepressants in a synergistic manner (Dhir and Kulkarni, 2007; Schramm et al., 2001).
5-HT1A receptor agonists, e.g., buspirone, gepirone, and ipsapirone, were found to have
antidepressant-like effects in animal models  (Schreiber and de Vry, 1993; Yocca, 1990).
Further, 5-HT2A/5-HT2C antagonists, e.g., methysergide and cyproheptidine, produce
antidepressant effects in depressed patients (Eison et al., 1990).
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Rolipram, a phosphodiesterase 4 (PDE4) inhibitor, also appears to have
antidepressant activity (O’Donnell, 1993; Fleishchhacker et al., 1992), but its clinical
efficacy compared with other antidepressants has been questioned (Hebenstreit et al.,
1989).  Although rolipram increases cyclic AMP by inhibiting its degradation, its effects
are not mimicked by forskolin, an activator of adenylyl cyclase (O’Donnell, 1993).
Rolipram was believed to increase NE turnover (Kehr et al., 1985) and the firing rate of
neurons in the LC (Scuvee-Moreau et al., 1987).  The antidepressant activity of rolipram
has led to the hypothesis positing an inbalance between adenylyl cyclase/protein kinase A
(PKA) systems and phospholipase C/PKC systems in depression (Wachtel, 1983).
Substance P antagonists and corticotropin releasing hormone (CRH) antagonists are
two new classes of putative antidepressants.  MK869, a substance P antagonist that
blocks neurokinin-1 receptors (NK1R), has been found to be as effective as paroxetine in
a 6-week double-blind trial in outpatients (Kramer et al., 1998; Maubach et al., 1999),
although there have been subsequent failures in clinical trials (Herpfer and Lieb, 2005).
The clinical failures suggest that, in addition to NK1R, other neurokinin receptors might
be involved in the modulation of stress-related behaviors and that exclusive blockade of
the NK1R might not be sufficient to produce consistent anxiolytic and antidepressant
effects.  NK2 (saredutant) and NK3 (osanetant) antagonists have been found to produce
anxiolytic- and antidepressant-like effects in gerbils (Salome et al., 2006).  Of special
interest might be compounds that block more than one receptor type, e.g., NK1/2R
antagonists or NK1/2/3R antagonists (Herpfer and Lieb, 2005; Griebel et al., 2001;
Steinberg et al., 2001). The other mechanism of antidepressant effect of substance P
antagonist is not clear, but may be associated with desensitization of α-2 adrenergic
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receptors or 5-HT1A serotonergic autoreceptors (Fisher et al., 2007; Froger et al., 2001;
Santarelli et al., 2001). CRH mediates hypothalamic-pituitary-adrenal (HPA) axis
function, including autonomic and behavioral responses to acute and chronic stress
(Owens and Nemeroff, 1993; Arborelius et al., 1999).
1.2 Delayed onset of antidepressant effects
The therapeutic actions of antidepressant drugs develop gradually over time with
repeated treatment (Frazer and Benmansour, 2002; Nelson et al., 2004; Wong and
Licinio, 2001).  This is sometimes referred to as the “therapeutic lag” and appears to be a
graded response that is somewhat symptom-dependent, rather than a lack of any
therapeutic effect followed by its emergence (Katz et al., 2004; Frazer, 2000).
Both pharmacokinetic and pharmacodynamic mechanisms may underlie the
progressively developing effects of antidepressants.  Drugs such as desipramine have
relatively long half-lives and their metabolites often have even longer half-lives (Ziegler
et al., 1978).  Thus, accumulation of both parent drug and active metabolites can occur
with repeated treatment (Ordway et al., 2005).  Further, it appears that the lipophilic
nature of many antidepressants, including desipramine, contributes to their accumulation
in membranes, where they have the potential to interact with the NET to an extent greater
than would be predicted from plasma concentrations (Zhu et al., 2004; Mandela and
Ordway, 2006).
α-2 Adrenergic receptors, located presynaptically on noradrenergic neurons, regulate
neuronal firing and NE release by a negative feedback mechanism.  Excessive synaptic
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NE inhibits α-2 adrenergic receptors and subsequently reduces the release of NE.
Studies to date indicate that α-2 adrenergic autoreceptors remain largely functional after
chronic desipramine treatment (Garcia et al., 2004; Lapiz et al., 2007b) and likely cannot
account for time-dependent changes resulting from such treatment.
The 5-HT1A serotonergic autoreceptor plays a role in the effects of SSRIs treatment,
because this receptor regulates neuronal firing and 5-HT release (Pineyro and Blier,
1999; Celada et al., 2004).  It has been found that somantodetric 5-HT1A autoreceptors are
densensitized after chronic fluoxetine or sertraline treatment, which might be one of the
mechanisms underlying the SSRIs-induced antidepressant-like effect. The receptor
desensitization occurs at the level of effector coupling (Ase et al., 2001); a decrease in
presynaptic 5-HT1A receptor G-protein coupling is observed after chronic fluoxetine
treatment.
Repeated desipramine treatment causes other neuronal changes that may contribute
to antidepressant activity, including increased expression of cAMP response element
binding protein (CREB) and brain-derived neurotrophic factor (BDNF; Nibuya et al.,
1996) and neurogenesis in the dentate gyrus of the hippocampus (Santarelli et al., 2003;
Kodama et al., 2004; Chen at al., 2006; Sairanen et al., 2005).  These findings could be
involved in the delayed onset of antidepressants, since they require sufficient time to
develop.  In many cases of neuronal adaptation produced by antidepressant treatment,
e.g., down-regulation of β-adrenergic receptors, the antidepressant-induced adaptation is
homeostatic, i.e., in opposition to the acute drug effect.  This contrasts with the
progressive, unidirectional development of antidepressant effects in the clinical setting
(Katz et al., 2004).  It appears that similar neuroadaptive changes occurr for the long-term
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effects of SSRIs.  Using quantitative autoradiography, a marked reduction of 3H-cyano-
imipramine binding to the SERT is observed after chronic paroxetine or sertraline
treatment.  Similarly, using homogenate binding with 3H-citalopram, SERT binding sites
in the rat prefrontal cortex are reduced after chronic paroxetine or sertraline treatment
(Gould et al., 2006).  Accordingly, the SERT reuptake activity (i.e., clearance) in the
CA3 region of hippocampus is reduced after chronic treatment with SSRIs such as
paroxetine and sertraline; desipramine does not affect SERT function (Benmansour et al.,
2002).  The extracellular 5-HT concentration, measured by in vivo microdialysis, is
elevated in the hippocampus and caudate nucleus in the awake monkey after 3-day
fluoxetine treatment (Smith et al., 2000).
1.3 Animal models of depression
The lack of fully validated animal models retards depression research to some
degree; the symptoms of depression (e.g. depressed mood, feeling of worthlessness,
guilty and suicidality) are not easily produced in laboratory animals.  Also, the genetic
causes of depression cannot be replicated in animals since the depression vulnerability
genes are still unknown.  The dilemma is that animal depression models are needed to
explore the mechanism of depression, but such models can only be developed after
mechanisms underlying depression are better understood.  Animal behaviors that model
particular aspects of depression, e.g. impairment of cognition, abnormal psychomotor
activity, responses to stresses and pleasurable stimuli, appetite, and sleep can be
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evaluated, as can behavior that exhibits sensitivity to antidepressant treatment (Table
1.1).
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Table 1.1 Examples of animal models used in depression research
Model Features
Forced-swim test Antidepressants decrease immobility time in
a cylinder of water; lack of movement
thought to represent a state of despair
(Porsolt et al., 1977).
Tail-suspension test Antidepressants increase the struggling time
of mice when suspended by the tail; lack of
movement thought to represent a state of
despair; Used in mice only.
Differential-reinforcement-low-rate 72-s
operant schehdule
Antidepressants reduce the response rate and
increase the reinforcement rate (O’Donnell,
2005)
Chronic mild stress The animals subjected to random sequence
of mild stresses, i.e. cold, restrain, cages
tilting, disruption of light-dark cycle,
develop a series of abnormal behavioral and
physiological responses. These
abnormalities are corrected by chronic
antidepressant. (Willner, 1997)
Learned helplessness The animals are exposed to inescapable foot
shock and then develop escape deficit. This
deficit is reversed by chronic antidepressants
(Chen et al., 2001; Shirayama et al., 2002;
Vollmayr and Henn, 2001).
Olfactory bulbectomy Chemical or surgical lesions of olfactory
cause hyperactivity and other abnormal
behaviors, which are reversed by chronic
antidepressants (Kelly et al., 1997)
Open space swim test Antidepressants increase the swimming
distance (Sun and Alkon, 2005).
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1.4 Molecular structure and function of NET and SERT
The duration and the intensity of noradrenergic and serotonergic neurotransmitter
action are controlled by plasma membrane-bound transporters.  After release into the
synapse, neurotransmitters activate pre- or postsynaptic receptors.  The termination of
synaptic transmission is mostly completed by reuptake back into neurons or uptake into
glial cells by neurotransmitter transporters (Figure 1.1).
The NET and SERT belong to a family of Na+/Cl- dependent symporters that also
include transporters for dopamine, glycine, and GABA (Amara, 1992; Masson et al.,
1999).   Electrochemical energy derived from the inward gradient of Na+, provided by
Na+/K+-ATPase, drives the intracellular accumulation of neurotransmitter via the NET or
SERT.  Binding of Na+ and then Cl- is a prerequisite for the substrate to bind to the
transporter (Trendelenburgh, 1999).  Following the binding of substrate, both Na+ and Cl-
are co-transportered along with the substrate into the cytoplasm.
Both NET and SERT proteins include 12 transmembrane domains and sites for
glycosylation and phosphorylation (Figure 1.2).  Analysis of NET and SERT structure
reveals important information regarding the residues and domains responsible for NET
function, substrate binding, drug binding, phosphorylation and regulation.  The NET
protein consists of 617 (human NET and rat NET) or 615 (bovine NET) amino acids
(Pacholczyk et al., 1991).  Both amino and carboxy termini of the NET are located on the
cytoplasmic side.  The NET contains a large hydrophilic loop between TMD3 and
TMD4, within which are located the canonical sites for N-linked glycoslation (Blakely,
1994).  Inability to N-glycosylate the NET is associated with reduced protein stability,
surface trafficking, and transporter activity (Melikian et al., 1994).  Addition of a
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carbohydrate moiety was shown to significantly increase uptake (Melikian et al., 1994;
Nguyen and Amara, 1996).  It is likely that glycosylated NET proteins are expressed on
the membrane and non-glycosylated forms are retained in the cytoplasm, which makes
the glycosylation site a poteintial domain for regulation of NET function.  In addition to
glycosylation sites, there are sites of potential phosphorylation by PKC within the
intraceullar part of the NET.  For example, the phosphorylation of threonine-258 and
serine-259 located at the small intracellular loop between DM4 and DM5 is linked to
PKC-mediated NET protein internalization (Jayanthi et al., 2006).  Several sites of
phosphorylation by other protein kinases also have been found.  Threonine-30, threonine-
58, and serine-502 are potential PKA phosphorylation sites.  Threonine-19 and threonine-
583 are potential phosphorylation sites for casein kinase II (CKII) (Jayanthi et al., 2006).
The predicted topological structure of SERT is very similar with the NET.  The SERT
also has N-linked glycosylation sites on the large extracellular loop between TMD 3 and
TMD4 as well as homologous, potential phosphorylation sites.
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Figure 1.1 Schematic representation of neurotransmission steps at a synapse. The
neurotransmitter is synthesized in the presynaptic neuron, stored in synaptic vesicles by
the VNT, and released by exocytosis. The neurotransmitter then binds to receptors as an
effector, and is removed from the synaptic cleft by membrane-bound neurotransmitter
transporters (NET or SERT) through the reuptake process in presynaptic or postsynaptic
neurons and/or glial cells (Masson et al., 1999).
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Figure 1.2 Schematic representation of the human NET.  Large black circles indicate
potential phosphorylation sites for PKC; large gray circles indicate potential
phosphorylation sites for other kinases (Jayanthi et al., 2006).
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Figure 1.3 Alignment of the amino acid sequence of
human NET and rat SERT.  The putative α-helical
membrane spanning domains (I - XII) are indicated by
bars. Conserved residues are shaded (Pacholczyk et al.,
1991; Blakely et al., 1991; Hoffman et al., 1991).
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1.5 Noradrenergic reuptake inhibitors and selective serotonin reuptake inhibitors
NRIs and SSRIs elevate synaptic NE and 5-HT levels, respectively, by blocking the
NET or SERT.  The first tricyclic antidepressant, imipramine, elicited antidepressant
effects by inhibiting NET and SERT with some unfavorable side effects due to
antihistaminic, antiadrenergic, and anticholinergic effects (Ban, 2001).  Other tricyclic
antidepressants exhibit some selectivity for inhibition NE reuptake, e.g, desipramine,
protriptyline, and nortriptyline, or 5-HT reuptake, e.g., clomipramine; however, the side
effect profiles were still unfavorable.  The introduction of fluoxetine in 1988 provided a
safer treatment alternative to the tricyclic antidepressants since its side effect profile was
significantly improved.  However, some have questioned whether the SSRIs are as
efficacious at treating depression as the tricyclic antidepressants (Song, 1993).  The
thought that actions on both noradrenergic and serotonergic neurotransmission may be
advantageous led to the development of venlafaxine and duloxetine, which inhibit both
the NET and SERT and which have a favorable side-effect profile (Shelton, 2004).  The
development of reboxetine, a potent, selective, and specific NE reuptake inhibitor, shifts
from focusing on the 5-HT system to the NE system.  In vitro, reboxetine is about 120-
fold more potent at blocking NE reuptake than 5-HT reuptake (Wong et al., 2000).
Extensive clinical study indicated that reboxetine is a clinically active, efficacious, and
well tolerated antidepressant (Berzewdski et al., 1997).
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Table 1.2 Structure of antidepressants and Ki values for inhibition of NET and
SERT
Structure Antidepressant [
3H]5-HT uptake
inhibition
Ki (nM)
[3H]NE uptake
inhibition
Ki (nM)
Imipramine 20 ± 2 142 ± 8
Desipramine 163 ± 5 3.5 ± 0.6
Protriptyline 3.4 161
Fluoxetine 20 ± 2 2186 ± 142
Sertraline 3.3 ± 0.4 1716 ± 151
Venlafaxine 102 ± 9 1644 ± 84
*Reboxetine 1070 ± 3 8 ± 4
Data were obtained in HEK and *MDCK cells expressing hSERT and hNET (White et
al., 2005; Wong et al., 2000; Sanchez and Hyttel, 1999; Zhou, 2004)
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1.6 Regulation of NET
The NET is regulated by several intraceullar signaling molecules including cAMP,
PKA, PKC, p38 MAPK, Ca2+, CaM kinase II, protein phosphatases P1/PP2A, and ATP.
cAMP and PKA
cAMP, produced by activation of adenylyl cyclase, is a key component linking
upstream G protein-coupled receptors to downstream signaling cascades, e.g., activation
of PKA.  Research on the regulation by cAMP and PKA of NET activity has yielded
results that are not consistent across cell lines or species.  For example, membrane
permeable cAMP analogue 8 Br-cAMP induces a dose-dependent reduction of NET
activity in bovine adrenal medullary chromaffin cells (Bunn et al., 1992).  However, 8
Br-cAMP doesn’t change the NET activity in SK-N-SH (Apparsundaram et al., 1998b)
and SK-N-SH-SY5Y cells (Bonisch et al., 1998).  Forskolin, a compound that increases
intracellular cAMP by directly activating adenylyl cyclase, shows biphasic effects on
NET activity in chromaffin cells.  At a low concentration, forskolin increases in NET
activity; while at a high concentration it inhibits NET activity (Bunn et al., 1992).  Bryan-
Lluka et al. (2001) found that short-term (15 min) or long-term (24 h) treatment with
forskolin decreases NET activity in PC12 cells.  However, in COS7 cells transiently
transfected with rat NET cDNA, short-term treatment with forskolin does not affect NET
activity, while long-term treatment increases the NET activity (Bryan-Lluka et al., 2001).
Taken together, these data suggests that cAMP regulation is not a general mechanism in
NET regulation but is cell line- and species-dependent.
20
PKC
The NET is the target for PKC; phosphorylation sites for this kinase have been shown
for this transporter.  β-PMA, a PKC activator, reduces NET activity and surface
expression in HEK-293 and LLC-PK1 cells stably transfected with hNET
(Apparsundaram et al., 1998a) as well as rat placental trophoblasts (Jayanthi et al., 2004).
The decreased NET activity is characterized by a decrease in maximum transport velocity
(Vmax) and a slight decrease in substrate affinity (Km).  This reduction is primarily due to
the internalization of surface NET protein (Jayanthi et al., 2004).  Site-directed
mutagenesis reveals that threonine-258 and serine-259 on the hNET are phosphorylated
by PKC and that this results in transporter internalization (Jayanthi et al., 2006).  NET
activity also is reduced by the protein phosphatase 1/protein phosphatase 2A (PP1/2A)
inhibitors okadaic acid and calyculin A; these compounds prevent dephosphorylation
(Bauman et al., 2000).
P38 MAPK
A trafficking-independent mode of NET and SERT regulation that is sensitive to p38
MAPK has been identified in RBL-2H3, RN46A, and CHO cells transfected with either
NET or SERT (Zhu et al., 2004; Zhu et al., 2005).  NET activity measured by NE uptake
assay is stimulated by anisomycin, a p38 MAPK activator.  Also, SB203580, a p38
MAPK inhibitor, blocks anisomycin-induced activation of NET.  In comparison with
trafficking-depedent, PKC-dependent regulation in which the surface transporter density
changes with unchanged catalytic activation, anisomycin treatment does not change
maximal transport capacity (Vmax) but significantly reduces the affinity (Km), indicating a
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trafficking-independent regulation mode.  Moreover, a reduced displacement of
[125I]RTI-55, a competitive antagonist of 5-HT, from the SERT was observed, suggesting
a reduced affinity of SERT for 5-HT.  The observation that inhibiton of PP2A by okadaic
acid and calyculin A reverses anisomycin-induced activation of the transporters indicates
that PP2A is downstream of the p38 MAPK signaling pathway.  At high concentrations,
PP2A inhibitors reduce transporter activity, which might be due to the actions of PKC
and subsequent sequestration of surface transporters.
Ca2+ and CaM kinase II
Extraceullar Ca2+ plays an important role in NET activity.  NET activity in PC12 cells
shows a robust increase after incubation with 0.3-10 mM Ca22+ (Uchida et al., 1998).
Intraceullar Ca2+ released from endoplastic reticulum also is important in regulating NET
activity.  IP3 receptors located on the membrane of the endoplasmic reticulum regulate
release of Ca2+ stores.  2-APB, an IP3 receptor inhibitors, reduces NET activity by
inhibiting the Ca2+ release from endoplasmic reticulum in SH-SY5Y cells (Amano et al.,
2006) and rat cerebral cortex slices (unpublished data).  Ca2+/calmodulin dependent
kinase II (CaMKII) is able to directly phosphorylate the trasnporter and increase NET
activity by translocation of NET from the cytoplasm to the membrane.  Myosin light
chain kinase (MLC kinase) also enhances NET activity by phosphorylation of specific
amino acid residues on the transporter.  CaMKII and MLC kinase inhibitors robustly
inhibit Ca2+-dependent increases in NET activity.  External Ca2+ regulates transporter
activity by increasing NE uptake through CaM kinase II and MLC kinase rather than
decreasing NE uptake via the PKC signaling pathway, suggesting that NET activity is
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regulated by both an external Ca2+ activation-induced pathway and an internal pathway
regulating release of Ca2+ stores.
ATP
ATP is an important molecule in biological systems, providing the energy for a
variety of cellular functions.  ATP is present in the vesicles that store neurotransmitters,
which raises the possibility that ATP might be a co-transmitter.  Geffen and Livett (1971)
found that ATP is released with NE during depolarization.  Further study shows that the
high-affinity uptake of NE in PC12 cells is increased in the presence of Ca2+ and 0.1µM
ATP or ATP-gamma-S, an analog of ATP (Hardwick et al., 1989).  This ATP-induced
increase of NE uptake is reduced by App(NH)p, a competitive antagonist of ATP
(Hendley et al., 1988).  NE uptake is inhibited when the Ca2+ and Mg2+ are both absent
from the incubation medium, suggesting that divalent cations are required for ATP to
have its effect on NE uptake.
Regulation of the NET by neurotransmitters
The following neurotransmitters are found to be involved in the regulation of NET
activity: acetylcholine, insulin, GABA, angiotensin, nerve growth factor, natriuretic
peptides,  and nitric oxide.  Some are to be discussed below.
Acetylcholine
The muscarinic acetylcholine receptor agonist methacholine significantly reduces
NET maximum transport velocity with no change in Km value in SK-N-SH cells
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(Apparsundaram et al., 1999).  Methacholine treatment decreases NET binding sites
measured by 3H-nisoxetine in intact cells but not in total membrane factions. These
studies provide evidence in support of G-protein coupled receptor-mediated regulation of
the NET.
Insulin
Insulin is a hormone involved in regulating glucose homeostasis.  The effect of
insulin on NET activity has been studied in SK-N-SH and PC12 cells.  Acute insulin
treatments increases NE uptake in a time- and dose-dependent manner with enhancement
of NE transport capacity (Vmax) without an alteration in the Km for NE (Apparsundaram
et al., 2001).  Acute insulin treatment decreases NE uptake in PC12 cells (Figlweicz et
al., 1993a) and this decrease may be due to the effect of insulin on the transporter gene
transcription, as insulin is found to decrease NET mRNA expression in LC of the rat
(Figlewicz et al., 1993b).  The insulin receptor is a tyrosine kinase that phosphorylates
substrate proteins, including the insulin receptor substrate (IRS) family. Once
phosphorylated, the IRS binds to and activates its downstream proteins including
phosphatidylinositol 3-OH kinase (PI3K).  Tyrosine kinase and PI3K inhibitors produce
time- and concentration-dependent reduction of NE uptake, indicating that constitutive
tyrosine kinase and PI3K activity is necessary for NET activity (Apparsundaram et al.,
2001).  Effects of tyrosine kinase and PI3K inhibitors on basal NET uptake might
contribute to a loss of cell surface NET protein expression (Apparsundaram et al., 2001).
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Nitric oxide
Nitric oxide is a signaling molecule in the cardiovascular system and central nervous
system.  After exposure to the NO donor S-nitroso-N-acetylpenicillamine (SNAP), NET
activity is reduced through a cyclic GMP-independent manner in CHO cells (Kaye et al.,
2000), indicating a potential regulatory role for nitric oxide in modulating NET activity.
However, in SK-N-SH cells, SNAP treatment shows an elevation of uptake activity
(Apparsundaram et al., 1998a). More research is needed to explore the molecular
mechanism of nitric oxide.
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CHAPTER TWO
Norepinephrine transporter regulation mediates long-
term behavioral effects of antidepressant desipramine
This chapter is identical to a manuscript, which has been published in
Neuropsychopharmacology, 2008 Apr 16. [Epub ahead of print]
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2.1 Abstract
The relationship between the ability of repeated desipramine treatment to cause down-
regulation of the norepinephrine transporter (NET) and produce antidepressant-like
effects on behavior was determined.  Treatment of rats with 15 mg/kg/day desipramine
reduced NET expression, measured by 3H-nisoxetine binding and SDS-
PAGE/immunoblotting, in cerebral cortex and hippocampus and reduced the time of
immobility in the forced-swim test.  The antidepressant-like effect on forced-swim
behavior was evident two days following discontinuation of desipramine treatment when
plasma and brain levels of desipramine and its major metabolite desmethyl-desipramine
were not detectable.  Reduced NET expression resulted in reduced norepinephrine
uptake, measured in vitro, and increased noradrenergic neurotransmission, measured in
vivo using microdialysis.  Overall, the dose-response and time-of-recovery relationships
for altered NET expression matched those for production of antidepressant-like effects on
behavior.  The importance of increased noradrenergic neurotransmission in the persistent
antidepressant-like effect on behavior was confirmed by demonstrating that it was
blocked by inhibition of catecholamine synthesis with alpha-methyl-p-tyrosine.  The
present results suggest an important role for NET regulation in the long-term behavioral
effects of desipramine and are consistent with clinical data suggesting that enhanced
noradrenergic neurotransmission is necessary, but not sufficient, for its antidepressant
actions.  Understanding the mechanisms underlying NET regulation in vivo may suggest
novel targets for therapeutic intervention in the treatment of depression.
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2.2 Introduction
The therapeutic actions of antidepressant drugs develop gradually over time with
repeated treatment (Frazer and Benmansour, 2002; Nelson et al., 2004; Wong and
Licinio, 2001).  This is sometimes referred to as the “therapeutic lag” and appears to be a
graded response that is somewhat symptom-dependent, rather than a lack of any
therapeutic effect followed by its emergence (Katz et al., 2004; Frazer, 2000).  This
delayed activity has raised questions regarding the relevance of the acute neurochemical
effects of antidepressants, such as enhancement of monoaminergic neurotransmission, to
their long-term effects on behavior.  It has been argued that since the acute
neurochemical effects manifest early, they cannot, in and of themselves mediate the
slower developing therapeutic effects.  However, while enhancement of monoaminergic
activity may not be sufficient to produce antidepressant effects, it does appear to be
necessary.  This is evident from the finding that inhibition of synthetic enzymes for
norepinephrine (NE) or 5-HT results in a rapid return of symptoms in depressed patients
treated successfully with desipramine or fluoxetine, respectively (Charney, 1998; Miller
et al., 1996a).  Further, inhibition of catecholamine synthesis with alpha-methyl-p-
tyrosine (AMPT) increases depressive symptoms in patients with seasonal affective
disorder (Lam et al., 2001).  Similarly, reduction of 5-HT synthesis with para-
chlorophenylalanine or a tryptophan-free amino acid drink reverses symptom remission
induced by serotonin reuptake inhibitors (SRIs) (Salomon et al., 1993).
Both pharmacokinetic and pharmacodynamic mechanisms may underlie the
progressively developing effects of antidepressants.  Drugs such as desipramine have
relatively long half-lives and their metabolites often have even longer half-lives (Ziegler
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et al., 1978).  Thus, accumulation of both parent drug and active metabolites can occur
with repeated treatment (Ordway et al., 2005).  Further, it appears that the lipophilic
nature of many antidepressants, including desipramine, contributes to their accumulation
in membranes, where they have the potential to interact with the NE transporter (NET) to
an extent greater than would be predicted from plasma concentrations (Zhu et al., 2004;
Mandela and Ordway, 2006).
At early stages of desipramine treatment, noradrenergic neurotransmission is
enhanced as a direct consequence of transporter blockade (See et al., 1992).
Subsequently, dynamic, adaptive neuronal changes occur, such as down-regulation of β-
adrenergic receptors (Frazer and Conway, 1984; Ordway et al., 1988; Duncan et al.,
1993), desensitization of presynaptic α-2 adrenergic receptors (Sacchetti et al., 2001),
and down-regulation of the NET (Weinshenker et al., 2002).  In many cases of neuronal
adaptation, e.g., down-regulation of β-adrenergic receptors, the antidepressant-induced
adaptation is homeostatic, i.e., in opposition to the acute drug effect.  This contrasts with
the progressive, unidirectional development of antidepressant effects in the clinical
setting (Katz et al., 2004).  Further, studies to date indicate that α -2 adrenergic
autoreceptors remain largely functional after chronic desipramine treatment (Garcia et al.,
2004; Lapiz et al., 2007b) and likely cannot account for time-dependent changes resulting
from such treatment.  However, antidepressant-induced NET regulation appears to be
consistent with the clinical data.  It shows a time-course consistent with the delayed
therapeutic effects and parallels the gradual onset of antidepressant-induced effects on
depressive symptoms (Benmansour, et al., 2002; Katz et al., 2004).  Repeated, but not
acute, treatment with desipramine reduces NET expression in brain, determined by 3H-
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nisoxetine binding and Western blotting (Benmansour et al., 2004; Zhu et al., 2002).
This may be a direct effect of desipramine, rather than being secondary to increased
synaptic concentrations of NE, since it also occurs in vitro with PC12 and human
neuroblastoma cells (Zhu and Ordway, 1997; Zhu et al., 2005), as well as HEK-293 cells
transfected with the NET (Zhu et al., 1998).
 The goal of the present study was to determine the relationship between effects of
repeated desipramine treatment on NET expression and function in the brain and its
antidepressant-like effects on behavior.  This was determined by assessing the effects of
repeated desipramine treatment on NET expression and function in cerebral cortex and
hippocampus, noradrenergic neurotransmission using in vivo microdialysis, and effects
on behavior using the forced-swim test.  The results indicate that repeated treatment with
desipramine down-regulates the NET in the cerebral cortex and hippocampus, reducing
NE uptake, which results in increased noradrenergic neurotransmission and
antidepressant-like effects on behavior.
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2.3 Materials and Methods
Animals
Male Sprague-Dawley rats (Harlan, Indianapolis, IN), weighing 300-350g, were
housed 2 per cage in a temperature-controlled room (22 - 23° C) with a 12-h on/12-h off
light cycle (lights on at 6:00 AM).  Food and water were freely provided.  Blind
observations were used throughout all behavioral testing, which was carried out from
1:00 PM – 5:00 PM in a quiet room.  All procedures were reviewed and approved by the
Animal Care and Use Committees of West Virginia University Health Sciences Center
and the University of Texas Health Sciences Center at San Antonio, and are consistent
with the NIH “Guidelines for the Care and Use of Laboratory Animals” (NIH publication
No. 80-23, revised 1996). 
Chronic desipramine administration
Rats were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and
implanted subcutaneously with osmotic minipumps (model 2ML2, Alzet Corporation,
Palo Alto, CA) preloaded with either vehicle (50% saline, 40% DMSO, and 10% ethanol)
or desipramine (Sigma-Aldrich, St Louis, MO) at a concentration that delivered 5, 10, or
15 mg/kg/day of the free base (Benmansour et al., 2004).  Minipumps were removed,
under anesthesia, 14 days later.  Rats were tested for antidepressant-like behavior in the
forced-swim test 2 – 8 days after pump removal and discontinuation of desipramine
treatment.  Following the completion of the behavioral tests, rats were killed by
decapitation, their brains removed, and cerebral cortex and hippocampus dissected for
neurochemical analyses.
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Forced-swim test
The forced-swim test was carried out as described previously (Porsolt et al., 1977;
Zhang et al., 2006).  Plexiglas cylinders (40 cm high and 18 cm in diameter) were filled
with water (30 cm depth, 22 – 23 °C); at this depth, rats could not touch the bottom of the
cylinder with their tails or hind limbs.  On day 1 (i.e., 1 day after cessation of
desipramine treatment), the rats were pre-tested for 15 min to develop an immobility
posture after initial escape-oriented movements (Cryan et al., 2002).  On day 2 (2 days
after cessation of desipramine treatment), rats were subjected to the 5-min forced-swim
test and immobility time was recorded; immobility was defined as floating on the surface
of the water with the only movement being that required to keep the head above water.
Some rats were subjected to 5-min forced-swim testing 5 or 8 days after the end of the
desipramine treatment regimen (15-min pre-test after 4 or 7 days, respectively), in order
to determine the time of recovery.  Finally, in some tests, rats were administrated 150 or
300 mg/kg AMPT (Sigma-Aldrich, St Louis, MO) 4 hours prior to the 5-min forced-
swim test, to examine the effects of catecholamine depletion on chronic desipramine-
induced changes in immobility.
SDS-PAGE/Immunoblotting of NET protein in the rat brain
Cerebral cortex and hippocampus were homogenized in TEVP buffer (10 mM Tris
base, 5 mM NaF, 1 mM Na3VO4, 1 mM EDTA, 1 mM EGTA, 320 mM sucrose; pH 7.4)
with a glass homogenizer and centrifuged at 1,000 × g for 20 min at 4° C.  The
supernatant was centrifuged at 20,000 × g for 30 min to obtain a crude synaptosomal
fraction (Lin et al., 1998; Wyszynski et al., 1998; Dunah and Standaert, 2001).  The
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pellets were re-suspended and solubilized with RIPA buffer (50 mM Tris, 150 mM NaCl,
2% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 0.1% Triton X-100;
pH 8.0) containing protease inhibitors (Roche, Indianapolis, IN).   Protein content of
membrane lysate was measured using the bicinchoninic acid protein assay (Smith et al.,
1985; Pierce, Rockford, IL).   Equal amounts of protein from both control and treated rats
were mixed with 2X Laemmli sample buffer (Bio-Rad, Hercules, CA) and boiled at 100°
C for 3 min.  Samples were loaded onto 8% polyacrylamide gels for electrophoresis and,
after separation, transferred to the nitrocellulose membranes.  The membranes were
blocked in TBST buffer containing 5% nonfat milk for 2 h at room temperature, washed
with TBST buffer, and incubated overnight at 4° C with a specific polyclonal antibody
generated against a unique 22 amino acid peptide sequence mapping to the first
extracellular domain of the NET (Chemicon, Temecula, CA).  After washing with TBST,
membranes were incubated for 1 h at room temperature with horseradish peroxidase-
conjugated goat anti-rabbit immunoglobulin G (Pierce, Rockford, IL).  The labeled
protein bands were detected by chemiluminescence imaging (Bio-Rad, Hercules, CA)
and quantified by densitometry.  Comparisons of treatment effects were carried out
within single gels.
3H-Nisoxetine binding assay
3H-Nisoxetine binding to the NET was carried out as described previously (Tejani-
Butt et al., 1990; Bryan-Lluka et al., 2001).  Briefly, half of the entire cerebral cortex and
hippocampus were homogenized in 5 ml of ice-cold binding buffer (50 mM Tris base,
120 mM NaCl, 5 mM KCl; pH 7.4) using a Polytron (Brinkman Instruments, Westbury,
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NY) and then centrifuged at 36,000 × g for 10 min at 4° C.  The supernatant was
discarded, the pellet re-suspended in ice-cold binding buffer, centrifuged at 36,000 × g
for 10 min at 4°  C, and the pellet re-suspended in binding buffer to obtain a protein
concentration of 1 mg/ml as assayed using the bicinchoninic acid method (Smith, 1985;
Pierce, Rockford, IL).  Triplicate tubes containing 100 µl incubation buffer (total
binding) or 100 µl desipramine (final concentration 50 µM; non-specific binding), 100 µl
tissue sample, and 50 µl 3H-nisoxetine (final concentration 5 nM; 72 Ci/mmol,
PerkinElmer, Boston, MA) were incubated in a shaking ice bath for 4 h.  Non-specific
binding (i.e., in the presence of 50 µM desipramine) was approximately 10% of total
binding.  Bound 3H-nisoxetine was captured by rapid filtration through glass fiber filters
(GF/B Brandel, Gaithersburg, MD) that were pre-soaked in 5% polyethyleneimine, under
vacuum with a cell harvester (Brandel, Gaithersburg, MD).  Filters were washed twice
with ice-cold binding buffer and radioactivity determined by liquid scintillation counting.
3H-NE uptake assay
Uptake assays were carried out as described previously (Apparsundaram et al.,
1998a,b; Vizi et al., 2004).  Fresh rat cerebral cortex and hippocampus were placed in
ice-cold Krebs-Ringer/HEPES (KRH) buffer (125 mM NaCl, 5.2 mM KCl, 1.2 mM
CaCl2, 1.4 mM MgSO4, 1.2 mM KH2PO4, 5 mM glucose, 20 mM HEPES, 0.2 mg/ml
ascorbic acid and 100 µM pargyline; pH 7.4) gassed with 95% O2 / 5% CO2.  The tissues
were cut into 0.4 mm slices using a McIlwain tissue chopper (Brinkmann, Westbury,
NY).  Slices were separated by gentle shaking and washed with oxygenated KRH buffer.
Uptake assays were performed by incubating the tissue slices with 30 nM 3H-NE (10.9
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Ci/mmol, PerkinElmer, Boston, MA) for 10 min at 37° C.  Assays were terminated by
rapid washing of slices with 0.5 ml of ice-cold KRH buffer three times.  Buffer was
aspirated and slices were then sonicated in 10% trichloroacetic acid and centrifuged at
30,000 × g for 2 min.  3H-NE in the supernatant was quantified by liquid scintillation
counting.  Nonspecific uptake was determined in the presence of 20 µM desipramine.
Specific uptake was determined by subtracting nonspecific uptake from total uptake.
Measurement of extracellular NE in the medial prefrontal cortex (mPFC) by in vivo
microdialysis
At the same time the osmotic pumps were implanted, rats were placed in a stereotaxic
frame with the incisor bar set at -3.3 mm.  A microdialysis guide cannula (CMA/12;
CMA Microdialysis, North Chelmsford, MA), aimed at the mPFC, was implanted at
coordinates AP + 2.6 mm from Bregma, ML +1.4 mm from midline, DV -1.7 mm from
dura.  The guide cannula was anchored to the skull and an obdurator was inserted.  The
wound was sutured, topical antibiotic applied, and each rat returned to its home cage.  On
the testing day, the obdurator was removed and a microdialysis probe, with molecular
weight cutoff of 20 kDa and 4 mm of active membrane, was inserted into the guide
cannula; the probe extended 4 mm beyond the tip of the guide, centering the active
membrane within the mPFC.  The probe was perfused with artificial cerebrospinal fluid
(147 mM NaCl, 2.5 mM KCl, 1.3 mM CaCl2, 0.9 mM MgCl2; pH 7.4) at a flow rate of
1.0 µl/min.  After a 2 h equilibration period, four 30 min samples (30 µl) were collected
into tubes containing 2.5 µl of stabilizing solution (0.2 µM EDTA, 0.2 µM ascorbic acid,
0.2 M perchloric acid).  NE in the microdialysis samples was measured by high-
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performance liquid chromatography (HPLC) with coulometric detection (Coulochem2,
ESA Inc., East Chelmsford, MA).  The amount of NE in each sample was quantified
against a calibration curve run daily, ranging from 0 to 25 pg, with a detection limit of 0.5
pg.
Measurement of plasma and brain desipramine and desmethyl-desipramine
The measurement of desipramine and its primary metabolite desmethyl-desipramine
was carried out using a modification of a method described previously (Argenti and
D’Mello, 1994).  Plasma and brain were collected for analysis and stored at -70° C until
assay.  To 500 µl of plasma (either sample or blank standard) were added 100 µl of
internal standard solution (imipramine 200 ng/ml) followed by 100 µl of ammonium
hydroxide.  The plasma was then extracted with 1 ml l-butanol (20%) in hexane (pH 11)
for 15 min on a reciprocating shaker.  After separation of the phases by centrifugation at
2,500 x g at 25° C for 3 min, the organic layer was transferred to fresh glass culture tubes
and evaporated to dryness with nitrogen gas at 34° C.  Each sample was reconstituted
with 100 µl mobile phase (70:30 0.025 M KH2PO4:acetonitrile).
Half of the brain was homogenized in 8 ml carbonate buffer (0.1 M NaCO3, pH 12).
Aliquots (2 ml) of homogenates were transferred to glass tubes and 2 µg internal standard
(imipramine) was added along with 3 ml l-butanol (20%) n-hexane to both samples and
blank brain standards.  The mixture was shaken for 15 min and centrifuged at 2,500 x g at
25° C for 3 min.  The organic phase was transferred to a glass tube and the extraction was
repeated again.  The organic phase was evaporated by nitrogen gas and reconstituted to a
100 µl volume with mobile phase.
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Chromatography was conducted using a reversed-phase column (Waters Symmetry
Shield RP C18 4.6 mm x 150 mm, Milford, MA) and a 50 µl injector loop.  The column
temperature was ambient and the flow rate was set at 1.2 ml/min.  The fluorescence of the
eluent was monitored at an excitation wavelength of 260 nm with an emission
wavelength of 360 nm.  For desipramine and desmethyl-desipramine determinations,
recovery during extraction exceeded 90% and the lower limit of quantification was 25 ng.
Measurement of β-adrenergic receptor density
β-Adrenergic receptor density was determined as described previously (O’Donnell,
1990).  The right cerebral cortex was homogenized in 2 mM N-2-hydroxyethyl-
piperazine-N’-2-ethanesulfonic acid (HEPES) and 1 mM ethylenediamine tetra-acetic
acid (EDTA) buffer (pH 7.75) for 15 sec using a Polytron homogenizer.  The homogenate
was centrifuged at 40,000 x g for 20 min.  The supernatant was removed and the wash
procedure was repeated 4 times.  The final pellet was suspended in SHM buffer (10 mM
HEPES, 150 mM NaCl, 10 mM MgCl2 ; pH 7.75).  Saturation experiments were carried
out to determine the density of the β-1 and β-2 adrenergic receptors.  Membrane
suspensions were incubated in triplicate at 37˚ C for 30 min with 125I-pindolol (50-1000
pM) alone, 125I-pindolol and 100 nM CGP20712A (to block binding of IPIN to β-1
adrenergic receptors), or 125I-pindolol plus 100 µM isoproterenol (to define nonspecific
binding).  The reaction was stopped by the addition of 6 ml of ice-cold SHM, and the
samples were filtered over a vacuum through Schleicher and Schuell No. 25 glass fiber
filters.  The filters were washed twice with 3 ml of ice-cold SHM buffer and counted for
radioactivity using a gamma counter at an efficiency of 75%.
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Statistical analysis
The data were analyzed by one-way analyses of variance (ANOVA) followed by
Tukey’s or Bonferroni’s post-hoc tests.  Data are presented as means ± SEM and
differences are considered statistically significant when p values are less than 0.05.
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2.4 Results
Effects of repeated desipramine treatment on NET expression and behavior in the
forced-swim test
The relationship between the effects of chronic desipramine treatment on NET
expression and its effects on behavior in the forced-swim test, a preclinical test predictive
of antidepressant activity, was examined.  Treatment of rats with desipramine for 14 days
reduced NET expression in a dose-dependent manner, as indicated by a reduction of the
specific binding of 3H-nisoxetine to the NET in preparations of cerebral cortex
(F(3,16)=4.33, p < 0.05; Figure 2.1A) and hippocampus (F(3,16)=4.34, p < 0.05; Fig. 2.1A).
Down-regulation of the NET also was demonstrated using SDS-PAGE/immunoblotting
of preparations of cerebral cortex (F(3,16)=4.75, p < 0.05; Fig. 2.1B) and hippocampus
(F(3,15)=13.10, p < 0.001; Fig. 2.1B).  Importantly, this NET down-regulation was
observed two days after discontinuation of chronic desipramine treatment, a time when
plasma and brain concentrations of desipramine and desmethyl-desipramine were
undetectable (i.e., below the 25 ng detection limit of the assay).  By comparison, one hour
after acute treatment with 10 mg/kg desipramine, which causes similar effects on forced-
swim behavior, plasma concentrations (mean ± S.D.) were 0.5 ± 0.3 (desipramine) and
0.09 ± 0.02 (desmethyl-desipramine) µg/ml and brain concentrations were 3.4 ± 0.1
(desipramine) and 0.09 ± 0.03 (desmethyl-desipramine) µg/g protein.  In parallel with the
down-regulation of the NET, chronic desipramine also produced a dose-dependent
reduction in the duration of immobility in the forced-swim test (F(3,18)=91.23, p < 0.001;
Fig. 2.1C).  This was evident two days after discontinuation of chronic desipramine
treatment and paralleled the reduction of NET expression (Fig. 2.1B).  This treatment
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also reduced the Bmax for 
125I-pindolol binding to β-1 adrenergic receptors in cerebral
cortex (control:  73.3 ± 4.6; two days post-desipramine treatment:  40.7 ± 3.4 fmol/mg
protein; n=5/group; p < 0.01); β-2 adrenergic receptor density was unchanged.
Recovery of NET expression and behavioral effects following discontinuation of
repeated desipramine treatment
Chronic treatment with desipramine reduced NET expression and produced a
persistent antidepressant-like effect in the forced-swim test.  Experiments were carried
out to examine the relationship between changes in NET expression and behavior.  Rats
were treated chronically with 15 mg/kg/day desipramine for 14 days and subjected to the
forced-swim test 2, 5, or 8 days after the end of desipramine treatment (i.e., removal of
the osmotic pumps).  Rats then were killed and brains regions reserved for assessment of
NET expression and function; NET expression was determined using 3H-nisoxetine
binding and Western blotting and NET activity by measurement of 3H-NE uptake in
vitro.
A significant reduction of NET binding sites, measured by 3H-nisoxetine binding,
was evident two days after the discontinuation of chronic desipramine treatment in the
cerebral cortex (F(3,19)=8.59, p < 0.001; Fig. 2.2A) and hippocampus (F(3,19)=3.22, p <
0.05; Fig. 2.2A).  The NET binding sites were partially recovered five days, and fully
recovered eight days, post-treatment.  Consistently, decreased expression of NET also
was observed by SDS-PAGE/immunoblotting two days after the discontinuation of
chronic desipramine treatment in the cerebral cortex (F(3,12)=6.98, p < 0.01; Fig. 2.2B)
and hippocampus (F(3,12) = 4.26, p < 0.05; Fig. 2.2B).  The down-regulation of the NET
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protein expression was partially reversed five days, and completely recovered eight days,
post-treatment.  The time-course of NET expression and activity were paralleled by
behavioral effects in the forced-swim test.  Rats tested two days following the end of
chronic desipramine treatment displayed a reduced duration of immobility in the forced-
swim test (F(3,18)=27.15, p < 0.001; Fig. 2.2C).  This antidepressant-like effect was
partially reversed five days and completely disappeared eight days post-treatment.
The NET activity, determined by measurement of uptake of 3H-NE into cerebral
cortical and hippocampal slices in vitro, exhibited a pattern similar to NET expression.
NE uptake was significantly reduced two days after the end of chronic desipramine
treatment and returned to control levels by eight days post-treatment in both cerebral
cortical (F(4,19)= 3.92, p < 0.05; Fig. 2.2D) and hippocampal slices (F(4,21)=26.35, p <
0.001; Fig. 2.2D).
Extracellular NE concentration in mPFC after chronic desipramine treatment
Overall, the results described above indicate that repeated desipramine treatment
reduced NET expression in cerebral cortex and hippocampus, resulting in a persistent
antidepressant-like effect on behavior that was not dependent on the presence of
desipramine.  Such a reduction in NET expression and function would be expected to
result in enhanced noradrenergic neurotransmission in the brain since the primary method
of inactivation, i.e., reuptake, would be impaired.  To examine this, the extracellular
concentration of NE was measured in the mPFC by in vivo microdialysis.  A
representative photomicrograph of a cresyl violet-stained section in which the
microdialysis probe track was localized to mPFC is shown in (Figure 2.3A).  It was found
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that the basal NE concentration was increased more than two-fold two days after the
discontinuation of repeated desipramine treatment (F(3,50) = 20.14, p < 0.001; Fig. 2.3B).
The extracellular NE concentration returned to control values by five days post-treatment.
This period of enhanced noradrenergic neurotransmission was consistent with that of
reduced NET expression and function, as well as the persistent effects in the forced-swim
test (see above).  Also, consistent with persistently increased extracellular NE
concentration during chronic desipramine treatment, the density of β-1 adrenergic
receptors in cerebral cortex, determined by 125I-pindolol (200 pM) binding, was reduced
two days following the end of the repeated-treatment regimen (control:  29.8 ± 1.7; two
days post-desipramine:  12.8 ± 1.8 fmol/mg protein; n=5/group; p < 0.01); β-1 receptor
density was not different from control levels five and eight days post-treatment (27.2 ±
1.9 and 30.8 ± 3.2 fmol/mg protein, respectively; n=5/group).
Effect of catecholamine depletion on the persistent effects of desipramine treatment
in the forced-swim test
In order to determine whether enhanced noradrenergic neurotransmission was
necessary for the persistent antidepressant effect in the forced-swim test, a NE depletion
approach was utilized, similar to that used to assess the role of noradrenergic
neurotransmission in the clinical actions of desipramine (Miller et al., 1996).  Two days
after the end of chronic desipramine treatment, when the NET expression was reduced
and noradrenergic neurotransmission increased, rats were treated with the AMPT, an
inhibitor of tyrosine hydroxylase, the rate-limiting enzyme for NE biosynthesis.  AMPT
(150 mg/kg or 300 mg/kg, i.p.) was administrated 4 h before the forced-swim test to rats
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that had been treated chronically with vehicle or desipramine.  AMPT treatment resulted
in a dose-dependent loss of the persistent, antidepressant-like effect of chronic
desipramine in the forced-swim test (F(5,35) =17.64, p < 0.001; Fig. 2.4A).  An acute dose
of 150 mg/kg AMPT was effective in reversing the actions of chronic desipramine
treatment; this dose of AMPT did not affect behavior in the forced-swim when
administered alone.  Administration of 300 mg/kg AMPT also reversed the persistent
behavioral effect of desipramine, but when administered alone it produced a depressant-
like effect on forced-swim behavior (F(5,35) =17.64, p < 0.05; Fig. 2.4A).
43
2.5 Discussion
The present results show a relationship between desipramine-induced down-
regulation of the NET and antidepressant effects on behavior.  These exhibit similar dose-
response and time-of-recovery relationships.  Importantly, the down-regulation of the
NET results in antidepressant effects on behavior, even when there is no drug present to
inhibit NE transport.  Consistent with this, NET knockout mice show a similar
antidepressant-like effect in forced-swim and tail-suspension tests, due to reduced
clearance rates of NE (Xu et al., 2000).  It has been suggested that the functional
consequence of down-regulation of monoamine transporters is greater than
pharmacological inhibition (Klimek et al., 1997) due to its noncompetitive nature versus
the competitive nature of pharmacological inhibition.  The results of the microdialysis
experiment indicate that reduced NET expression does result in increased extracellular
concentrations of NE, indicative of enhanced noradrenergic neurotransmission, similar to
what is observed when the NET is inhibited acutely by desipramine (Lapiz et al., 2007a).
Clinical actions of antidepressants develop gradually over weeks of treatment (Frazer
and Benmansour, 2002; Katz et al., 1996; Katz et al., 2004), leading to the suggestion
that neuroadaptive processes underlie the long-term behavioral effects.  In the present
study, it was found that the expression and activity of NET were significantly reduced by
repeated desipramine treatment after a two-day washout, when plasma and brain
antidepressant drug concentrations were not detectable.  The density of postsynaptic β-1
adrenergic receptors also was decreased two days after chronic administration of 15
mg/kg/day desipramine for 14 days, consistent with previous findings (Ordway et al.,
1988).  Desipramine-induced reduction in immobility is associated with decreased β-1
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adrenergic receptors; both effects are blocked by co-administration of β-1 adrenergic
receptors antagonists (Kitada et al., 1986; Mancinelli et al., 1991).  Both β-1 adrenergic
receptor and NET expression were significantly reduced two days after chronic
desipramine treatment, and recovered after 8 days of withdrawal, suggesting that
regulation of both NET and β-1 adrenergic receptors is involved in adaptive mechanisms
for noradrenergic neurons.  The increased synaptic NE concentration that results from
NET down-regulation likely contributes to the down-regulation of β-1 adrenergic
receptors (Ordway et al., 1988).  Repeated desipramine treatment causes other neuronal
changes that may contribute to antidepressant activity, including increased 3H-GTP
binding to Gs protein coupled to β-1 adrenergic receptors (Yamamoto et al., 1990),
increased CREB mRNA expression (Nibuya et al., 1996), induction of BDNF expression
(Nibuya et al., 1996), and increased neurogenesis in the dentate gyrus and hippocampus
(Santarelli et al., 2003; Kodama et al., 2004; Chen at al. 2006; Sairanen et al., 2005).
The mechanism underlying desipramine-induced down-regulation of the NET has not
been fully determined.  In addition to being observed in vivo (Zhu et al., 2002;
Weinshenker et al., 2002), it also has been shown in vitro in cell lines expressing the
NET.  Using Western blotting, NET expression in SK-N-BE(2)M17 cells was shown to
be decreased by 3 – 14 days of exposure to desipramine (Zhu et al., 1998).  This suggests
that desipramine-induced NET regulation is, at least in part, a direct effect and not
secondary to an increase in the extracellular concentration of NE.  In vitro, both the NET
and serotonin transporter (SERT) have been shown to be regulated via a PKC- (PKC)
dependent pathway (Apparsundaram et al., 1998a,b; Jayanthi et al., 2005).  Desipramine
and other NE reuptake inhibitors may stimulate some specific factors in the PKC
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pathway and trigger a signal transduction cascade activating protein kinase C.  Activation
of PKC by β-PMA down-regulates and internalizes membrane-associated NET (Jayanthi
et al., 2004).  The NET-PP2A-Ar complex and the NET-syntaxin 1A complex have been
shown to be involved in the PKC-mediated process (Sung et al., 2005; Sung and Blakely,
2007).  It has been reported that inhibition of IP3 receptors by 2-aminoethoxydiphenyl
borate and xestospongin C reduces the Vmax of NET, as well as NET expression (Amano
et al., 2006).  Given that inhibition of IP3 receptors simultaneously results in PKC
inhibition, it appears that the regulation of the NET is under the control of calcium/PKC-
mediated mechanisms.  However, this has not been demonstrated in vivo.  Such a
demonstration might suggest novel means to produce NET down-regulation and
antidepressant effects on behavior.
Whether the down-regulation of NET is mediated by altered NET gene transcription
has been a point of investigation.  Previous studies using HEK-293 and SK-N-BE(2)M17
cells have shown that desipramine-induced reduction of NET expression primarily is due
to translocation or increased degradation of the NET, but have not ruled out altered
transcription (Zhu et al., 1998; Zhu et al., 2002).  However, in vivo, it was found that
NET mRNA expression in the locus ceruleus is elevated after chronic desipramine
treatment (Szot et al., 1993).  Further, it was found that the mRNA expression of another
monoamine transporter, the SERT, in the raphe nucleus is unchanged following chronic
treatment with the SRI paroxetine (Benmansour et al., 1999).
While the present study focused on NET expression and the effects of desipramine, it
is likely that similar mechanisms are involved in the long-term effects of SRIs.  Repeated
treatment with drugs from this pharmacological class reduces SERT expression and
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increases serotonergic neurotransmission.  Using quantitative autoradiography, a marked
reduction of 3H-cyano-imipramine binding to the SERT is observed after chronic
paroxetine or sertraline treatment.  Similarly, using 3H-citalopram homogenate binding,
SERT binding sites in the rat prefrontal cortex are reduced after chronic paroxetine or
sertraline treatment (Gould et al., 2006).  Accordingly, the SERT reuptake activity (i.e.,
clearance) in the CA3 region of hippocampus is reduced after chronic treatment with
SRIs such as paroxetine and sertraline; desipramine does not affect SERT function
(Benmansour et al., 2002).  The extracellular serotonin concentration, measured by in
vivo microdialysis, is elevated in the hippocampus and caudate nucleus in the awake
monkey after 3-day fluoxetine treatment (Smith et al., 2000).  However, to date, it has not
been reported whether enhanced, persistent down-regulation of the SERT results in
antidepressant effects on behavior, even when drug is not present.  Dual norepinephrine
and serotonin reuptake inhibitors, which may produce persistent effects on both
noradrenergic and serotonergic neurotransmission, may possess greater efficacy and a
more rapid onset of action (Millan, 2006).
 Among the adaptive changes that may underlie the long-term effects of
antidepressant treatment, NET and SERT regulation fit with the clinical data to a
considerable degree.  From a functional perspective, the direction of the long-term
change in transporter expression following antidepressant treatment is the same as that
seen with acute treatment with an antidepressant.  In both cases, there is a reduction in
transporter function and enhanced monoaminergic neurotransmission.  By contrast,
changes in monoaminergic receptor expression often are homeostatic, i.e., in opposition
to the effect of acute antidepressant treatment (Ordway et al., 1991).  Clinically, in
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untreated patients, it has been reported that reducing catecholamine activity with AMPT
or serotonergic activity with tryptophan depletion has no obvious effects on symptoms of
depression, indicating that monoamine deficiency itself is insufficient to cause symptoms
of depression (Miller et al., 1996b).  However, catecholamine depletion by AMPT results
in depression relapse in the patients treated chronically with NE reuptake inhibitors such
as desipramine, but not SRIs (Miller et al., 1996a; Bremner et al., 2003).  By contrast,
inhibition of serotonin synthesis with para-chlorophenylalanine or a tryptophan-free
amino acid drink reverses symptom remission caused by SRIs, but not NE reuptake
inhibitors (Miller et al., 1996a; Salomon et al., 1993).
It was found, consistent with these clinical findings, that inhibition of catecholamine
synthesis with AMPT reversed the persistent antidepressant-like effect of desipramine in
the forced-swim test.  Changes in both noradrenergic and dopaminergic
neurotransmission may contribute to this effect of AMPT (O’Donnell and Seiden, 1984).
A specific role for noradrenergic neurotransmission is suggested by the finding that NE-
deficient mice fail to respond to the behavioral effects of the NE reuptake inhibitor
desipramine.  Restoration of NE by l-threo-3,4-dihydroxyphenylserine (l-DOPS)
reinstates the behavioral effects of desipramine in these mice (Cryan et al., 2004).
Overall, the preclinical and clinical data suggest that enhanced monoaminergic
neurotransmission is necessary, but not sufficient, for producing antidepressant effects, at
least for those drugs that act via inhibition of reuptake.  A schema describing
pharmacological mechanisms thought to underlie the effects of desipramine is shown
(Fig. 4B).  Following acute treatment, desipramine inhibits the NET, reducing NE uptake,
which results in an increased extracellular NE concentration and an antidepressant-like
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behavioral response.  Two days following chronic desipramine treatment, when the
plasma and brain levels of desipramine and its major active metabolite are not detectable,
NET expression and function are reduced, resulting in enhanced noradrenergic
neurotransmission and an antidepressant response.  However, treatment with AMPT at
this time reduces noradrenergic neurotransmission, resulting in a loss of the
antidepressant-like response, consistent with clinical findings (Miller et al., 1996a).
Overall, the present results demonstrate a relationship between desipramine-induced
down-regulation of the NET and antidepressant-like effects on behavior.  NET down-
regulation, which was evident for at least two days following discontinuation of
treatment, persisted even in the absence of detectable levels of desipramine or its major
metabolite in plasma or brain.  NET down-regulation resulted in reduced NE uptake,
measured in vitro, and enhanced noradrenergic neurotransmission, measured in the mPFC
in vivo.   Neuroimaging studies have consistently implicated the mPFC in depression, and
in the response to antidepressant treatment (Dreyets, 2000).  Also consistent with clinical
data, it was found that the antidepressant-like effect that resulted from NET down-
regulation depended on the enhanced noradrenergic neurotransmission since it was lost
when NE synthesis was inhibited.  The present data provide support for the idea that NET
down-regulation may contribute to the long-term therapeutic effects of some
antidepressant drugs.  Understanding the mechanism of NET regulation in vivo, which in
vitro data suggest is due more to altered internalization and degradation than altered
transcription, may suggest novel targets for therapeutic intervention in the treatment of
depression.
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Figure 2.1 Dose-response functions were determined for the ability of chronic
desipramine treatment to reduce NET expression in the cerebral cortex and hippocampus,
determined by 3H-nisoxetine binding (A) and SDS-PAGE /immunoblotting with antisera
against the NET (B), and to reduce immobility time in the forced-swim test (C).  All
measures were determined two days after the end of the chronic treatment period, when
brain and plasma concentrations of desipramine and its metabolite desmethyl-
desipramine were not detectable (i.e., below the 25 ng detection limit of the assay).  Data
shown are means ± SEM of 5-6 rats per group. *p < 0.05, **p < 0.01, ***p < 0.001 vs.
control.
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Figure 2.2 The recovery time-course of chronic desipramine on NET expression in the
cerebral cortex and hippocampus, measured by 3H-nisoxetine binding (A) and SDS-
PAGE/immunoblotting with antisera against the NET (B).  The persistent antidepressant-
like effect in the forced-swim test was evident two days after the end of the chronic
treatment period, but dissipated by eight days (C).  The uptake of 3H-NE into tissue
slices, which reflects the activity of the NET, was reduced two days after discontinuation
of desipramine treatment, and returned to the control level after five to eight days (D).
Data shown are means ± SEM of 5-10 rats per group. *p < 0.05; **p< 0.01; ***p < 0.001
vs. control.
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Figure 2.3 Representative photomicrograph of a cresyl violet-stained section,
corresponding to Plate 9 in the atlas of Paxinos and Watson (1998), showing the
microdialysis probe track in mPFC on the right (arrow).  Brain regions are labeled on the
left side for clarity.  The guide cannula extended into the lower part of Cg1, and the 4 mm
active probe track extended from the uppermost part of area PrL to just below area IL,
thus including both major components of rat mPFC. Abbreviations: Cg1, cingulate
cortex, region 1; IL, infralimbic cortex; Pir, piriform cortex; PrL, prelimbic cortex (A).
Chronic 15 mg/kg/day desipramine treatment with 2 days washout significantly elevated
the tonic baseline of NE in mPFC, measured by in vivo microdialysis (B).  Data shown
are means ± SEM of 11-12 rats per group.  ***p < 0.001.
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Figure 2.4 To examine whether enhanced noradrenergic neurotransmission was
necessary for the persistent antidepressant-like effect in the forced-swim test, AMPT, an
inhibitor of tyrosine hydroxylase, was administered two days after the end of the chronic
desipramine treatment regimen.  AMPT reversed the antidepressant-like effect in the
forced-swim test, even at a dose where it did not affect behavior on its own (A).  The
changes in noradrenergic neurotransmission after acute and chronic desipramine
treatment are demonstrated in this diagram (B).  The membrane NET is blocked by acute
desipramine treatment, resulting in an increased synaptic NE concentration. Two days
after completion of chronic desipramine treatment, when the plasma and brain
concentrations of desipramine and its major active metabolite are not detectable, the
membrane NET is down-regulated.  Under this condition, the increase of synaptic NE
and antidepressant effect on behavior result not only from the direct blocking of NET by
the desipramine, but also from reduced NET expression and function.  Inhibition of NE
synthesis with AMPT reverses the increase in neurotransmission, resulting in a loss of
antidepressant efficacy, even though the NET is down-regulated.  Data shown are means
± SEM of 5-7 rats per group. *p < 0.05, ***p < 0.001 vs. control; ###p < 0.001 vs.
desipramine alone.
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CHAPTER THREE
Association of changes in norepinephrine and
serotonin transporter expression with the long-term
behavioral effects of antidepressant drug treatment
This chapter is identical to a manuscript, which was submitted to
Neuropsychopharmacology in July 2008.
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3.1 Abstract
Previous work has shown that repeated desipramine treatment causes down-
regulation of the norepinephrine transporter (NET), accompanied by persistent
antidepressant-like effects on behavior.  The present study examined whether this
mechanism generalizes to other antidepressant drugs and also is evident for the serotonin
transporter (SERT).  Treatment of rats for 14 days with 20 mg/kg/day protriptyline or 7.5
mg/kg/day sertraline reduced NET and SERT expression, respectively, in cerebral cortex
and hippocampus; these treatments also induced a persistent antidepressant-like effect in
the forced-swim test.  Increased serotonergic neurotransmission likely mediated the
persistent antidepressant-like behavioral effect of sertraline, since it was blocked by
inhibition of serotonin synthesis with para-chlorophenylalanine; a parallel effect was
observed previously for desipramine and noradrenergic neurotransmission.  Treatment
with 20 mg/kg/day reboxetine for 42, but not 14, days reduced NET expression;
antidepressant-like effects on behavior were observed for both treatment durations.
Treatment for 14 days with 70 mg/kg/day venlafaxine, which inhibits both the NET and
SERT, or 10 mg/kg/day phenelzine, a monoamine oxidase inhibitor, produced persistent
antidepressant-like effects on behavior without altering NET or SERT expression.  For all
drugs tested, reductions of NET and SERT protein were not accompanied by reduced
NET or SERT mRNA in LC or dorsal raphe nucleus, respectively.  Overall, the present
results suggest an important, though not universal, role for NET and SERT regulation in
the long-term behavioral effects of antidepressants.  Understanding the mechanisms
underlying transporter regulation in vivo may suggest novel targets for the development
of antidepressant drugs.
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3.2 Introduction
Antidepressants, in general, enhance noradrenergic and/or serotonergic
neurotransmission following acute administration (Millan, 2006).  For many
antidepressants, including the tricyclic antidepressants, serotonin reuptake inhibitors
(SRIs), norepinephrine reuptake inhibitors (NRIs), and serotonin-norepinephrine reuptake
inhibitors (SNRIs), this results from inhibition of the norepinephrine or serotonin
transporters (NET, SERT), which clear the transmitters from the synapse (Beyer et al.,
2002; Katz et al., 2004; Morilak and Frazer, 2004; White et al., 2005).  Some drugs
enhance monoaminergic neurotransmission by other mechanisms such as inhibition of
monoamine oxidase (Laux et al., 1995; Lopez-Munoz et al., 2007) or antagonism of
presynaptic α-2 adrenergic receptors (Charney et al., 1986; Dickinson, 1990; Millan et
al., 2000; Artigas et al., 2001).  While enhanced monoaminergic neurotransmission
appears to be an effect shared by antidepressants from different chemical and
pharmacological classes, its relationship to antidepressant efficacy is unclear since
therapeutic effects develop gradually over time with repeated treatment (Frazer and
Benmansour, 2002; Nelson et al., 2004; Katz et al., 2004).
This delayed clinical activity has raised questions regarding the relevance of the
acute neurochemical effects of antidepressants, including enhancement of
monoaminergic neurotransmission, to their long-term effects on behavior.  It is believed
that enhanced monoaminergic neurotransmission is not sufficient to produce an
antidepressant effect, since this neurochemical effect is manifested early, prior to
development of a clear, clinical effect.  However, enhanced monoaminergic activity
appears to be necessary for clinical activity.  This is evident from the finding that
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inhibition of synthetic enzymes for norepinephrine or serotonin results in a rapid return of
symptoms in depressed patients who have been treated successfully with desipramine or
fluoxetine, respectively (Charney, 1998; Miller et al., 1996a).  Recent work has
implicated antidepressant-induced down-regulation of NET and SERT in the brain as a
mechanism that may contribute to the long-term pharmacological effects of
antidepressant drugs (Hirano et al., 2005a; Thakker et al., 2005; Zhao et al., 2008).
Reduced NET or SERT expression would increase monoaminergic neurotransmission,
even in the absence of pharmacological inhibition of the transporters.
In a recent study, it was found that repeated treatment with desipramine, which is
relatively selective for inhibition of the NET relative to the SERT, reduces the expression
of the NET in cerebral cortex and hippocampus in a dose-dependent manner (Zhao et al.,
2008).  This was evidenced by reduced binding of 3H-nisoxetine and by SDS-
PAGE/immunoblotting using NET-specific antisera.  The reduced expression results in
reduced uptake of 3H-norepinephrine into tissue slices in vitro and increased extracellular
norepinephrine concentration in the prefrontal cortex measured in vivo using
microdialysis.  At all desipramine treatment conditions when the NET was found to be
down-regulated, an antidepressant-like effect on behavior was evident in the forced-swim
test.  Importantly, NET down-regulation and behavioral effects were observed even when
brain and plasma levels of desipramine and its major, active metabolite
desmethyldesipramine were not detectable.  Finally, as is observed in the clinical setting
(Lam et al., 2001; Miller et al., 1996a), the persistent antidepressant-like effect of
desipramine in the forced-swim test was lost when tyrosine hydroxylase was inhibited
with alpha-methyl-p-tyrosine (AMPT; Zhao et al., 2008).
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Other studies have reported that repeated treatment with antidepressant drugs reduces
the expression of the NET in the brain (Benmansour et al., 2004; Wong et al., 2000).
Similarly, some antidepressants, including SRIs, have been reported to reduce the
expression of the SERT (Benmansour et al., 1999; Benmansour et al., 2002; Gould et al.,
2003; Hirano et al., 2005a; Hirano et al., 2005b; Gould et al., 2006), resulting in
enhanced serotonergic neurotransmission.  Antidepressant-induced down-regulation of
the NET and SERT has been observed with cell lines in vitro (Zhu and Ordway, 1997;
Zhu et al., 1998; Horschitz et al., 2001; Zhu, 2005; Iceta et al., 2007).  This suggests that
the down-regulation may result from a direct effect of the drugs on the transporter and is
not secondary to increased extracellular concentrations of the transmitter.  Thus, NET and
SERT down-regulation may be effects caused by reuptake inhibitors and not by drugs
that increase monoaminergic neurotransmission by other mechanisms, such as inhibition
of monoamine oxidase.
While it appears that NET and SERT down-regulation with chronic treatment is an
effect shared by a number of antidepressant drugs that inhibit monoamine reuptake, it is
not clear to what extent this action contributes to the long-term behavioral effects of
antidepressants from different pharmacological classes; to date, this relationship has only
been investigated for desipramine.  The present study examined the effects of the
antidepressants protriptyline, reboxetine, sertraline, venlafaxine, and phenelzine on the
NET and SERT and assessed whether changes in their expression resulted in
antidepressant-like effects on behavior, similar to what has been observed with
desipramine (Zhao et al., 2008).  Protriptyline, a tricyclic antidepressant, produces
neurochemical and behavioral effects similar to those of desipramine (Crissman and
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O’Donnell, 2002; O’Donnell et al., 2005).  Reboxetine is an NRI that exhibits somewhat
greater selectivity for the NET vs. the SERT compared to desipramine and protriptyline
(Scates and Doraiswamy, 2000; Wong et al., 2000; Iversen, 2006).  Sertraline is an SRI
and is active in a number of antidepressant models (Benmansour et al., 1999;
Benmansour et al., 2002).  Venlafaxine, although classified as an SNRI, exhibits
markedly greater potency for inhibition of the SERT than the NET (Iversen, 2006).
Phenelzine, a monoamine oxidase inhibitor, does not interact directly with the NET or
SERT, but increases monoaminergic neurotransmission and has antidepressant activity
(Thase et al., 1995).  Overall, the present study shows that down-regulation of the NET or
SERT is produced by some antidepressants that interact with the transporters and that this
effect contributes to their long-term behavioral effects; however, persistent
antidepressant-like effects on behavior can, in some cases, be observed even when NET
or SERT expression is not altered.
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3.3 Materials and Methods
Animals
Male Sprague-Dawley rats (Harlan, Indianapolis, IN), weighing 300-350g, were
housed 2 per cage in a temperature-controlled room (22 - 23° C) with a 12-h on/12-h off
light cycle (lights on at 6:00 AM).  Food and water were freely provided.  Blind
observations were used throughout all behavioral testing, which was carried out from
1:00 PM – 5:00 PM in a quiet room.  All procedures were reviewed and approved by the
Animal Care and Use Committee of West Virginia University Health Sciences Center,
and are consistent with the NIH “Guidelines for the Care and Use of Laboratory
Animals” (NIH publication No. 80-23, revised 1996). 
Drugs administration
Rats were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and
implanted subcutaneously with osmotic minipumps (model 2ML2 or 2ML4, Alzet
Corporation, Palo Alto, CA) preloaded with either vehicle (50% saline, 40% DMSO, and
10% ethanol), protriptyline (Sigma-Aldrich, St Louis, MO), reboxetine (provided by
Institut de Recherches Servier, Croissy/Seine, France), sertraline (Tocris, Ellisville, MO)
or venlafaxine (Sigma-Aldrich, St Louis, MO) at concentrations that delivered 10 or 20
(protriptyline), 20 (reboxetine), 7.5  (sertraline), or 70 (venlafaxine) mg/kg/day of the free
base.  Minipumps were removed, under anesthesia, 14 days later.  However, for some rats
treated with reboxetine, minipumps were removed 21 days after implantation and new
minipumps were implanted, providing 42 days of drug administration. A dose of 10
mg/kg/day (i.p.) of the irreversible monoamine oxidase inhibitor phenelzine was
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administrated for 14 days.  Doses of each of the drugs used were chosen based on
previous reports of neuropharmacological activity (Ordway et al., 1991; Gould et al.,
2006).
Rats were tested for antidepressant-like behavior in the forced-swim test and
locomotor activity in the open-field test 2 days after pump removal or the last phenelzine
treatment; this minimized acute drug effects.  However, the behavioral tests for one group
treated with 10 mg/kg/day protriptyline were performed 1 day after the removal of
pumps.  Following the completion of the behavioral tests, rats were sacrificed by
decapitation, their brains removed, and cerebral cortex and hippocampus dissected for
measurement of NET and SERT using 3H-nisoxetine or 3H-citalopram binding and SDS-
PAGE/immunoblotting with specific antisera.  Also, locus coeruleus and raphe nucleus
were punched from surrounding tissue for real-time PCR measurement of NET and
SERT mRNA.
Forced-swim test
The forced-swim test was carried out as described previously (Porsolt et al., 1977;
Zhang et al., 2006).  Plexiglas cylinders (40 cm high and 18 cm in diameter) were filled
with water (30 cm depth, 22 – 23° C); at this depth, rats could not touch the bottom of the
cylinder with their tails or hind limbs.  On day 1 (i.e., 1 day after cessation of
antidepressant treatment), the rats were pre-tested for 15 min to develop an immobility
posture after initial escape-oriented movements (Cryan et al., 2002).  On day 2 (2 days
after cessation of chronic antidepressant treatment), rats were subjected to the 5-min
forced-swim test and immobility time was recorded; immobility was defined as floating
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on the surface of the water with the only movement being that required to keep the head
above water.  Some rats treated with 10 mg/kg/day protriptyline were subjected to 5-min
forced-swim testing one day after the end of the antidepressant treatment regimen, with
the 15-min pre-test on the last day of drug treatment.  Finally, in some tests, rats were
administered the tryptophan hydroxylase inhibitor p-chlorophenylalanine (PCPA, 300
mg/kg, i.p; Sigma-Aldrich, St Louis, MO) twice daily for three consecutive days, with the
last dose given 18 h before 5-min forced-swim test.  This was done to determine whether
reduced serotonergic neurotransmission blocked the antidepressant-like effect observed
in the forced-swim test following down regulation of the SERT; this paralleled previous
experiments examining the effects of reduced noradrenergic neurotransmission on
persistent antidepressant-like behavior observed following desipramine-induced down-
regulation of the NET (Zhao et al., 2008).
To ensure that any changes in immobility in the forced-swim test were not secondary
to increased locomotor activity, rats were observed in the open field test (Zhang et al.,
2008).  The floor of the open-field apparatus was divided into nine identical squares.
Rats were placed individually in the center and allowed to explore for 5 min; the number
of line crossings (with all four paws crossing a line) and rears were recorded.  None of
the treatments increased locomotor activity, so these data are not shown.
SDS-PAGE/Immunoblotting of SERT and NET protein in the rat brain
Cerebral cortex and hippocampus were homogenized in TEVP buffer (10 mM Tris
base, 5 mM NaF, 1 mM Na3VO4, 1 mM EDTA, 1 mM EGTA, 320 mM sucrose; pH 7.4)
with a glass homogenizer and centrifuged at 1,000 × g for 20 min at 4° C.  The
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supernatant was centrifuged at 20,000 × g for 30 min to obtain a crude synaptosomal
fraction (Lin et al., 1998; Wyszynski et al., 1998; Dunah et al., 2001).  The pellets were
re-suspended and solubilized with RIPA buffer (50 mM Tris, 150 mM NaCl, 2%
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 0.1% Triton X-100; pH
8.0) containing protease inhibitors (Roche, Indianapolis, IN).   Protein content of
membrane lysate was measured using the bicinchoninic acid assay (Smith, 1985; Pierce,
Rockford, IL).   Equal amounts of protein from both control and treated rats were mixed
with 2X Laemmli sample buffer (Bio-Rad, Hercules, CA) and boiled at 100° C for 3 min.
Samples were loaded onto 8% polyacrylamide gels for electrophoresis and, after
separation, transferred to nitrocellulose membranes.  The membranes were blocked in
TBST buffer containing 5% nonfat milk for 2 h at room temperature, washed with TBST
buffer, and incubated overnight at 4° C with a specific, rabbit polyclonal antibody
generated against a unique 22 amino acid peptide sequence mapping to the first
extracellular domain of the NET (Chemicon, Temecula, CA; Zhao et al., 2008) or a
peptide fragment of the C-terminus of the SERT (Santa Cruz, Santa Cruz, CA; Xie et al.,
2006).  After washing with TBST, membranes were incubated for 1 h at room
temperature with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G
(Pierce, Rockford, IL).  The labeled protein bands were detected by chemiluminescence
imaging (Bio-Rad, Hercules, CA) and quantified by densitometry using an NIH image
analysis program, and normalized to actin. Comparisons of treatment effects were carried
out within single gels/immunoblots.
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3H-Nisoxetine binding assay
3H-Nisoxetine binding to the NET was carried out as described previously (Tejani-
Butt et al., 1990; Bryan-Lluka et al., 2001). One-half of the cerebral cortex or
hippocampus was homogenized in 5 ml of ice-cold binding buffer (50 mM Tris base, 120
mM NaCl, 5 mM KCl; pH 7.4) using a Polytron (Brinkman Instruments, Westbury, NY)
and then centrifuged at 36,000 × g for 10 min at 4° C.  The supernatant was discarded, the
pellet re-suspended in ice-cold binding buffer, centrifuged at 36,000 × g for 10 min at 4°
C, and the pellet re-suspended in binding buffer to obtain a protein concentration of 1
mg/ml as assayed using the bicinchoninic acid method (Smith, 1985; Pierce, Rockford,
IL).  Triplicate tubes containing 100 µl incubation buffer (total binding) or 100 µl
desipramine (final concentration 50 µM; non-specific binding), 100 µl tissue sample, and
50 µl 3H-nisoxetine (final concentration 5 nM; 72 Ci/mmol, PerkinElmer, Boston, MA)
were incubated in a shaking ice bath for 4 h.  Non-specific binding (i.e., in the presence
of 50 µM desipramine) was approximately 10% of total binding.  Bound 3H-nisoxetine
was captured by rapid filtration through glass fiber filters (GF/B Brandel, Gaithersburg,
MD) that were pre-soaked in 5% polyethyleneimine under vacuum with a cell harvester
(Brandel, Gaithersburg, MD).  Filters were washed twice with ice-cold binding buffer
and radioactivity determined by liquid scintillation counting.
3H-citalopram binding assay
3H-Citalopram binding to the SERT was performed as described previously
(D’Amato et al., 1987; Gould et al., 2006).  One-half of the cerebral cortex or
hippocampus was homogenized in 5 ml of ice-cold binding buffer (50 mM Tris base, 120
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mM NaCl, 5 mM KCl; pH 7.4) using a Polytron (Brinkman Instruments, Westbury, NY)
and then centrifuged at 36,000 × g for 10 min at 4° C.  The supernatant was discarded, the
pellet re-suspended in ice-cold binding buffer, centrifuged at 36,000 × g for 10 min at 4°
C, and the pellet re-suspended in binding buffer to obtain a protein concentration of 1
mg/ml as assayed using the bicinchoninic acid method (Smith, 1985; Pierce, Rockford,
IL).  Triplicate tubes containing 100 µl incubation buffer (total binding) or 100 µl
fluoxetine (final concentration 50 µM; non-specific binding), 100 µl tissue sample, and
50 µl 3H-citalopram (final concentration 5 nM; 79 Ci/mmol, PerkinElmer, Boston, MA)
were incubated for 1 h with shaking at room temperature.  Non-specific binding (i.e., in
the presence of 50 µM fluoxetine) was approximately 10% of total binding.  Bound 3H-
citalopram was captured by rapid filtration through glass fiber filters (GF/B Brandel,
Gaithersburg, MD) that were pre-soaked in 5% polyethyleneimine under vacuum with a
cell harvester (Brandel, Gaithersburg, MD).  Filters were washed twice with ice-cold
binding buffer and radioactivity determined by liquid scintillation counting.
Measurement of NET and SERT mRNA by quantitative real-time PCR
Locus coeruleus (for NET mRNA) and dorsal and median raphe nucleus (for SERT
mRNA) were punched from the rat brain (Chamas et al., 1999; Chamas et al., 2004;
Paxinos and Watson, 1998; Zhu et al., 2002).  Total RNA was extracted using the Trizol
reagent (Invitrogen, Carlsbad, CA) and was kept in RNAlater buffer (Ambion, Austin,
TX) and stored at -80°  C.  Total RNA concentration was determined by
spectrophotometry and adjusted to 0.5 µg/µl.  The quality of the RNA was verified using
1% denaturing agarose gel electrophoresis.  Contaminating genomic DNA was
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eliminated by incubating with DNase mixture (Qiagen, Valencia, CA) at room
temperature for 20 min.  RNA was reverse transcribed to cDNA with high capacity
cDNA archive kit (Applied Biosystems, Foster City, CA).  The cDNA was subjected to
real-time PCR using TaqMan universal PCR Master Mix and ABI 7300 real-time PCR
system (Applied Biosystems, Foster City, CA).  Specific primers and probes were
purchased from pre-designed, pre-optimized TaqMan Gene Expression Assays (Applied
Biosystems, Foster City, CA).  Quantities of NET and SERT mRNA were normalized to
the 18s rRNA.  Analysis was performed using ABI-7300 system SDS software.
Statistical analysis
The data were analyzed by one-way analyses of variance (ANOVA) followed by
Tukey’s or Bonferroni’s post hoc tests.  When simple, paired comparisons between two
groups were conducted, two-tailed Student’s t-tests were used.  Data are presented as
means ± SEM and differences are considered statistically significant when p values are
less than 0.05.
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3.4 Results
The neurochemical and behavioral effects of repeated antidepressant treatment were
assessed 2 days after the end of the treatment period (i.e., osmotic minipump removal or
discontinuation of phenelzine injections), except for some tests with protriptyline (see
below).  This permitted assessment of persistent effects under conditions when brain and
plasma concentrations would be minimized (Zhao et al., 2008).  None of the treatments
increased locomotor activity, which could confound interpretation of results in the
forced-swim tests; however, one day following treatment with protriptyline, locomotor
activity was reduced (i.e., line crosses in the open-field test, to 65% of control; data not
shown).
Effects of protriptyline
The relationship between the effect of chronic protriptyline treatment on NET
expression and its effect on behavior in the forced-swim test was examined.  Treatment
of rats with 20 mg/kg/day protriptyline for 14 days, with a 2-day washout period, reduced
NET expression, as indicated by a reduction of the binding of 3H-nisoxetine to the NET
in preparations of cerebral cortex (F(4,21)= 5.75, p < 0.01; Fig. 3.1A) and hippocampus
(F(4,21)= 7.43, p < 0.001; Fig. 3.1A).  Down-regulation of the NET also was demonstrated
using SDS-PAGE/immunoblotting of preparations of cerebral cortex (F(2,12)= 12.19, p <
0.001; Fig. 3.1B) and hippocampus (F(2,12)= 13.81, p < 0.001; Fig. 3.1B).  Down-
regulation of NET expression was not observed 2 days following the end of treatment
with 10 mg/kg/day protriptyline for 14 days, but was seen 1 day following this treatment
(Fig. 3.1A).
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A persistent antidepressant-like effect in the forced-swim test was evident 2 days after
discontinuation of 14-day treatment with 20 mg/kg/day protriptyline or 1 day after
discontinuation of 14-day treatment with 10 mg/kg/day protriptyline  (F(4,25)= 10.00, p <
0.001; Fig. 3.1C); this paralleled the protriptyline-induced down-regulation of the NET.
No antidepressant-like effect on behavior was observed 2 days after chronic protriptyline
treatment at a dose of 10 mg/kg/day (Fig. 3.1C), consistent with the lack of NET down-
regulation at this treatment condition.
In order to determine whether the down-regulation of the NET resulted from a change
in gene transcription, NET mRNA expression in the locus coeruleus was measured by
quantitative RT-PCR.  The normalized, relative NET mRNA expression was not changed
2 days following the end of chronic treatment with 20 mg/kg/day protriptyline or 1 day
following the end of chronic treatment with 10mg/kg/day protriptyline (F(2,27)= 2.14, p >
0.05; Table 3.1).  Similarly, repeated treatment with 15 mg/kg/day desipramine, which
reduces NET protein expression (Zhao et al., 2008), also did not reduce NET mRNA in
locus coeruleus (p > 0.05; Table 3.1).
Effects of reboxetine
The relationship between the effect of chronic reboxetine treatment on NET
expression and its effect on behavior in the forced-swim test was examined.  Treatment
of rats with 20 mg/kg/day reboxetine for 6 weeks, with a 2-day washout, reduced NET
expression, as indicated by a reduction of the specific binding of 3H-nisoxetine to the
NET in preparations of cerebral cortex (F(2,12) =23.00; p < 0.0001; Fig. 3.2A) and
hippocampus (F(2,12) =3.78; p < 0.05; Fig. 3.2A); however, treatment for two weeks did
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not alter NET expression significantly.  By contrast, SERT expression (i.e., 3H-
citalopram binding) was not altered by reboxetine treatment, either in preparations of
cerebral cortex (F(2,14) =1.67; p > 0.05; Fig. 3.2B) or hippocampus (F(2,16) =0.68; p > 0.05;
Fig. 3.2B).
Down-regulation of the NET by six-week chronic reboxetine treatment also was
demonstrated using SDS-PAGE/immunoblotting of preparations of cerebral cortex (F(2,13)
=5.99; p < 0.05; Fig. 3.2C) and hippocampus (F(2,16) =2.94; p < 0.05; Fig. 3.2C).  By
contrast, this treatment did not alter SERT expression, measured by immunoblotting, in
either cerebral cortex or hippocampus (Fig. 3.2D).  Interestingly, repeated treatment with
15 mg/kg desipramine for 14 days reduced SERT expression in cerebral cortex and
hippocampus as evidenced using 3H-citalopram binding (40 – 50% reduction; data not
shown).
In parallel with the down-regulation of the NET, chronic treatment with reboxetine
for 6 weeks also produced a reduction in the duration of immobility in the forced-swim
test, indicative of an antidepressant-like effect (F(2,15) =34.01; p < 0.001; Fig. 3.2E).
Although the 2-week reboxetine treatment did not reduce NET expression in cerebral
cortex or hippocampus, an antidepressant-like effect still was observed in the forced-
swim test following this treatment (Fig. 3.2E).
In order to determine whether the down-regulation of NET resulted from a change in
NET gene transcription, NET mRNA expression in the locus coeruleus and SERT mRNA
expression in the dorsal and medial raphe nucleus were measured using quantitative RT-
PCR.  The normalized, relative NET mRNA expression in the locus coeruleus was
elevated, about 3-fold, 2 days after discontinuation of chronic reboxetine treatment (p <
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0.001; Table 3.1).  The normalized, relative SERT mRNA expression in the dorsal and
medial raphe nucleus was increased about 2.5-fold (p < 0.01; Table 3.1).
Effects of sertraline
Given the apparent relationship between the down-regulation of the NET by chronic
treatment with NRIs and persistent antidepressant-like effects in the forced-swim test, it
was of interest to also examine the relationship between changes in SRI-induced SERT
expression and behavior.  Rats were treated chronically with 7.5 mg/kg/day sertraline for
14 days and subjected to the forced-swim test 2 days after the end of sertraline treatment
(i.e. removal of the osmotic pumps), and SERT expression was determined in several
brain regions using 3H-citalopram binding and Western blotting.  Further, to determine
whether enhanced serotonergic neurotransmission was necessary for the persistent
antidepressant effect in the forced-swim test, a serotonin depletion approach was utilized,
similar to that used to assess the role of serotonergic neurotransmission in the clinical
actions of sertraline (Miller et al., 1996b).  Rats were treated with PCPA, an inhibitor of
tryptophan hydroxylase, the rate-limiting enzyme for serotonin biosynthesis.  PCPA (300
mg/kg, i.p.) was administrated twice daily for three consecutive days with the last dose
given 18 h before behavioral test (O’Leary et al., 2007) to rats that had been treated
chronically with vehicle or sertraline.
A significant reduction of SERT binding sites, measured using 3H-citalopram, was
evident 2 days after the discontinuation of chronic sertraline treatment in the cerebral
cortex (F(3,18)= 8.17, p < 0.01; Fig. 3.3A) and hippocampus (F(3,18)= 10.06, p < 0.001; Fig.
3.3A).  By contrast, NET expression (i.e., 3H-nisoxetine binding) was not altered by
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sertraline treatment, either in preparations of cerebral cortex (p > 0.05; Fig. 3.3B) or
hippocampus (p > 0.05; Fig. 3.3B).
The down-regulation of the SERT also was demonstrated using SDS-
PAGE/immunoblotting of preparations of cerebral cortex (F(3,16)= 6.94, p < 0.01; Fig.
3.3C) and hippocampus (F(3,16)= 14.37, p < 0.001; Fig. 3.3C).  By contrast, this treatment
did not alter NET expression, measured by immunoblotting, in either cerebral cortex or
hippocampus (Fig. 3.3D).
In parallel with the down-regulation of the SERT, chronic sertraline treatment also
produced an antidepressant-like effect in the forced-swim test, demonstrated by a
reduction of immobility time (F(3,19)= 19.57, p < 0.001; Fig. 3.3E).  Three-day, twice
daily treatment with 300 mg/kg/day PCPA, to reduce serotonin neurotransmission,
reversed the behavioral actions of chronic sertraline treatment, demonstrated by the
increased immobility time and reduced latency to immobility (Fig. 3.3E); PCPA, when
administered alone, did not affect behavior in the forced-swim test (Fig. 3.3E), nor did it
alter SERT expression (Fig. 3.3C).
There was a significant effect of sertraline administration on normalized, relative
SERT mRNA expression in the dorsal and median raphe nucleus (F(3,18)=28.5, p < 0.001;
Table 3.1).  Post hoc tests revealed that while chronic sertraline treatment did not change
the SERT mRNA expression, a significant decrease in SERT mRNA expression was
found in the groups treated with PCPA alone or in combination with chronic sertraline
(Table 3.1).
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Effects of venlafaxine
Given that venlafaxine inhibits both the NET and SERT, i.e. it is an SNRI, it was of
interest to explore the relationship between venlafaxine-induced changes in NET and
SERT expression and behavior.  Rats were treated chronically with 70 mg/kg/day
venlafaxine for 14 days and subjected to the forced-swim test 2 days after the end of
venlafaxine treatment.  NET and SERT binding sites were determined in several brain
regions using 3H-nisoxetine and 3H-citalopram binding.  NET and SERT protein
expression was determined by Western blotting.  Treatment of 70 mg/kg/day venlafaxine
did not alter NET (Fig. 3.4A) or SERT binding sites (Fig. 3.4B) in cerebral cortex and
hippocampus.  Consistently, NET and SERT protein expression in cerebral cortex and
hippocampus was not changed after chronic venlafaxine treatment (Fig. 3.4C, 3.4D).
However, in spite of the lack of any change in NET or SERT expression, an
antidepressant-like effect in the forced-swim test was observed two days after the end of
the chronic venlafaxine treatment period (p < 0.001; Fig. 3.4E).
Effects of phenelzine
To determine whether enhanced monoaminergic neurotransmission, independent of
NET or SERT inhibition, was sufficient to alter expression of the transporters, the effects
of the monoamine oxidase inhibitor phenelzine were determined.  Rats were treated with
10 mg/kg/day phenelzine (i.p.) for 14 days and subjected to the forced-swim test 2 days
after the end of the treatment period.  NET and SERT expression was then assessed in
cerebral cortex and hippocampus.
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 Phenelzine treatment did not alter NET or SERT expression in cerebral cortex or
hippocampus, measured by 3H-nisoxetine and 3H-citalopram binding (Fig. 3.5A, 3.5B)
and SDS-PAGE/immunoblotting (Fig. 3.5C, 3.5D).  However, a significant decrease in
immobility time in the forced-swim test was observed following chronic phenelzine
treatment (p < 0.001; Fig. 3.5E).
78
3.5 Discussion
In a previous study, the relationship between desipramine-induced down-regulation of
the NET and antidepressant effects on behavior was observed (Zhao et al., 2008).  The
down-regulation of the NET is associated with antidepressant effects on behavior, even
when there is no detectable drug present to inhibit norepinephrine reuptake.
Desipramine-induced down-regulation of the NET and the development of persistent
antidepressant-like effects on behavior develop gradually with repeated treatment,
consistent with the development of the clinical response to antidepressants (Frazer et al.,
2002; Katz et al., 1996, 2004; Gelenberg and Chesen, 2000).  This suggests that neural
adaptation resulting in enhanced monoaminergic neurotransmission may be a key
mechanism mediating antidepressant actions.  Consistent with this, it was found that
inhibition of catecholamine synthesis with AMPT reverses the persistent antidepressant-
like effect in the forced-swim test (Zhao et al., 2008); similar effects have been observed
in depressed patients treated with desipramine (Charney, 1998; Miller et al., 1996a).  The
results of the present study demonstrated that NET down-regulation appears to be
important for the actions of protriptyline and reboxetine, two other antidepressants that
interact with the NET.  Further, SERT down-regulation contributes to the long-term
behavioral effects of the SRI sertraline.
NET expression, measured by 3H-nisoxetine binding and SDS-
PAGE/immunoblotting, was reduced after 14 days of treatment with protriptyline or 42
days of treatment of reboxetine, similar to the effect observed after repeated treatment
with desipramine (Zhao et al., 2008). β-1 adrenergic receptor density also is reduced after
chronic desipramine, protriptyline, or reboxetine treatment (Ordway et al., 1991; Gould et
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al., 2003).  This suggests that NET down-regulation results in increased noradrenergic
neurotransmission; this has been verified experimentally for desipramine and reboxetine
treatment using in vivo microdialysis (Page and Lucki, 2002; Lapiz et al., 2007; Zhao et
al., 2008).
NET down-regulation in response to NRI treatment, in addition to being observed in
vivo (Zhu et al., 2002; Weinshenker et al., 2002; Zhao et al., 2008), also has been shown
in vitro in cell lines expressing the NET.  NET expression in SK-N-BE(2)M17 cells is
decreased following 3 – 14 days of exposure to desipramine (Zhu et al., 1998).  Chronic
desipramine-induced NET down-regulation also was observed with PC12 and human
neuroblastoma cells (Zhu and Ordway, 1997; Zhu et al., 2005), as well as HEK-293 cells
transfected with the NET (Zhu et al., 1998).  Because these cells lack synaptic
innervation, these findings suggest that desipramine-induced NET regulation is, at least
in part, a direct effect of occupation of the NET, and not secondary to an increase in the
extracellular concentration of NE.  Consistent with this interpretation, it was found that
chronic treatment with the monoamine oxidase inhibitor phenelzine, which increases
noradrenergic neurotransmission, does not down-regulate the NET.  However, it did
produce antidepressant-like effects in the forced-swim test.
In the present study, it was found that repeated treatment with the SRI sertraline
reduced SERT expression, measured using 3H-citalopram binding and SDS-
PAGE/immunoblotting.  Previously, it has been found that SERT density in the CA3
region of the hippocampus, assessed by quantitative autoradiography with 3H-
cyanoimipramine, is decreased by 80-90% by chronic sertraline or paroxetine treatment
(Benmansour, et al., 1999).  After 15 days of sertraline treatment, SERT binding sites are
80
reduced by 80%, accompanied by a marked reduction of serotonin clearance
(Benmansour et al., 2002).  SERT density in the dentate gyrus, lateral nucleus of the
amygdala, and dorsal raphe, measured by 3H-cyanoimipramine binding, is significantly
reduced after chronic paroxetine treatment (Gould et al., 2003).  Similarly, using 3H-
citalopram homogenate binding, SERT binding sites in the rat prefrontal cortex are
reduced after chronic paroxetine or sertraline treatment (Gould et al., 2006).  SERT
expression in mouse brain regions is reduced after chronic paroxetine treatment; this
effect persists for 120 h after 21 days of treatment (Hirano et al., 2005b).  In humans, it
has been reported that treatment with 40 mg/day citalopram for 8 days reduces SERT
binding sites in the diencephalon and brainstem (Kugaya et al., 2003).  To date, it had not
been determined whether persistent down-regulation of the SERT resulted in the
antidepressant effects on behavior.  In the present study, it was found that two days
following discontinuation of sertraline treatment, when SERT expression was reduced in
cerebral cortex and hippocampus, a persistent antidepressant-like effect in the forced-
swim test was observed.
In HEK cells expressing the SERT, its binding sites are reduced after a 3-day
incubation with 500 nM citalopram; this is accompanied by decreased maximal
transporter activity (Vmax) and an unchanged Km value (Horschitz et al., 2001).  In vitro,
down-regulation of SERT is associated with protein kinase C (PKC) activation-induced
phosphorylation of specific amino acid residues, which triggers translocation of SERT
from membrane to cytoplasm (Jayanthi et al., 2004; Sung et al., 2005; Sung et al., 2007;
Amano et al., 2006).  Qian et al. (1997) and Lau et al. (2008) also have shown that
stimulation of PKC causes internalization of cell-surface SERT protein.
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While treatment with the NRI reboxetine reduced NET expression without altering
the SERT, consistent with its reported selectivity (Wong et al., 2000; Millan et al., 2001;
Versiani et al., 1999), desipramine treatment reduced expression of both the NET and the
SERT.  This may result from a lack of selectivity for desipramine for the NET at the dose
tested (Iversen, 2006) or may be due to the effects of desipramine’s primary, active
metabolite desmethyldesipramine, which reaches concentrations similar to the parent
compound (Kozisek et al., 2007).  In preparations of rat brain, desmethyldesipramine
exhibits 12-fold greater affinity for the SERT compared with the NET;
desmethyldesipramine’s affinity for the SERT is similar to desipramine’s for the NET
(Deupree et al., 2007).  Thus, immediately after desipramine administration, when the
desipramine concentration is much higher than that of desmethyldesipramine, the
pharmacological effect of desipramine might be associated primarily with the NET, while
later as the concentration of the longer-lived metabolite desmethyldesipramine increases,
both SERT and NET may be involved.
Among the adaptive changes that may underlie the long-term effects of antidepressant
treatment, NET and SERT regulation fit with the clinical data to a considerable degree.
From a functional perspective, the direction of the long-term change in transporter
expression following antidepressant treatment is the same as that seen with acute
treatment with an antidepressant.  In both cases, there is a reduction in transporter
function and enhanced monoaminergic neurotransmission.  By contrast, changes in
monoaminergic receptor expression often are homeostatic, i.e., in opposition to the effect
of acute antidepressant treatment (Ordway et al., 1991).  Preclinically, AMPT partially
prevents the acute desipramine response, while a combination of AMPT and reserpine
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completely prevents the behavioral effects of acute desipramine (O’Leary et al., 2007);
this suggests that disruption of both catecholamine synthesis and vesicular storage and
release are required to completely block desipramine’s effects.  PCPA, a tryptophan
hydroxylase inhibitor (Koe and Weissman, 1966), completely reverses the
antidepressant-like effect produced by acute treatment with the SRIs fluoxetine and
citalopram (Page et al., 1999; O’Leary et al., 2007).  Clinically, in untreated patients, it
has been reported that reducing catecholamine activity with AMPT or serotonergic
activity with tryptophan depletion has no obvious effects on symptoms of depression,
indicating that monoamine deficiency itself is insufficient to cause symptoms of
depression (Miller et al., 1996b).  However, catecholamine depletion by AMPT results in
the return of symptoms of depression in depressed patients treated chronically with NRIs
such as desipramine, but not SRIs (Miller et al., 1996a; Miller et al., 1996b; Bremner et
al., 2003).  By contrast, inhibition of serotonin synthesis with PCPA or a tryptophan-free
amino acid drink reverses symptom remission caused by SRIs, but not NRIs (Miller et
al., 1996b; Salomon et al., 1993).
Consistent with these clinical data, it has been found in an earlier study that inhibition
of catecholamine synthesis with AMPT reverses the persistent antidepressant-like effect
of desipramine in the forced-swim test (Zhao et al., 2008); changes in both noradrenergic
and dopaminergic neurotransmission may contribute to this effect of AMPT (O’Donnell
and Seiden, 1984).  A role for noradrenergic neurotransmission is suggested by the
finding that NE-deficient mice fail to respond to the behavioral effects of the NRI
desipramine.  Restoration of noradrenergic function by l-threo-3,4-
dihydroxyphenylserine (l-DOPS) reinstates the behavioral effects of desipramine in these
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mice (Cryan et al., 2004).  In the present study, it was found that inhibition of serotonin
synthesis with PCPA reversed the persistent antidepressant-like effect of sertraline in the
forced-swim test. Overall, the preclinical and clinical data suggest that enhanced
monoaminergic neurotransmission is necessary, but not sufficient, for producing
antidepressant effects, at least for those drugs that act via inhibition of reuptake.
Whether the down-regulation of the NET or SERT is mediated by altered gene
transcription has been a point of investigation.  Previous studies using HEK-293 and SK-
N-BE(2)M17 cells have shown that desipramine-induced reduction of NET expression
primarily is due to translocation or increased degradation of the NET, but have not ruled
out altered transcription (Zhu et al., 1998; Zhu et al., 2002).  However, in vivo, it is found
that NET mRNA expression in the locus coeruleus is elevated after chronic desipramine
treatment (Szot et al., 1993).  Further, it is found that the SERT mRNA expression in the
raphe nucleus is unchanged following chronic treatment with SRIs (Benmansour et al.,
1999; Abumaria et al., 2007).  Lopez et al. (1994) found that the SERT mRNA level is
increased after chronic antidepressant treatment, while Lesch et al. (1993) reported a
decreased SERT mRNA level.  In vitro, the expression of NET mRNA in human
enterocyte-like cell line Caco-2 (Iceta et al., 2007) and SERT-expressing HEK293 cells
(Lau et al., 2008) is unaltered after chronic SRIs treatment.  In the present study, it was
found that NET mRNA expression in the rat locus coeruleus was unchanged after chronic
desipramine or protriptyline treatment, while it was elevated 3-fold after the 6-week
reboxetine treatment regimen.  Given that the change in NET protein expression
produced by these drugs is reduced, i.e., in the opposite direction, it is unlikely that
chronic antidepressant-induced down-regulation of the NET is regulated at the
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transcriptional level.  In fact, exposure to reboxetine for six weeks might trigger a
compensatory increase in transcription.  Changes in SERT mRNA also do not appear to
account for sertraline-induced changes in SERT protein expression.  However, while
sertraline treatment alone did not alter SERT mRNA, PCPA alone or in combination with
sertraline reduced it.  Interestingly, SERT mRNA expression in the raphe nucleus was
increased after the six-week reboxetine treatment; the mechanism mediating this effect
and its functional significance are unclear.
It seems that down-regulation of NET or SERT is not the only mechanism mediating
persistent antidepressant-like behavioral effects.  Treatment of rats with 20 mg/kg/day
reboxetine for two weeks did not reduce the NET expression but did produce an
antidepressant-like effect in the forced-swim test 2 days after the end of the treatment
period.  Further, 2-week treatment with 70 mg/kg/day venlafaxine treatment failed to
decrease the NET or SERT expression but still produced a persistent antidepressant-like
effect in the forced-swim test.  It also was reported that NET and SERT binding sites,
measured using quantitative autoradiography with 3H-citalopram, are not reduced in the
CA3 region of hippocampus after treatment for 21 days with 15 or 70 mg/kg/day
venlafaxine (Gould et al., 2006).  Similarly, chronic treatment with amitriptyline, a
tricyclic antidepressant that inhibits both the NET and SERT, also fails to reduce SERT
and NET binding sites (Owens et al., 1997).  The inability of venlafaxine to down-
regulate the NET or SERT following chronic treatment is not due to a lack of efficacy,
since treatment with 70 mg/kg/day causes a down-regulation of β-1 adrenergic receptors
in the same rats in which no down-regulation of the transporters is observed (Gould et al.,
2006).  Also, chronic venlafaxine produces a dose-dependent attenuation of the
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hypothermic response of rats to acute treatment with 8-OH-DPAT, a serotonin-1A
receptor agonist, similar to the effects produced by sertraline and citalopram (Hensler et
al., 2003; Rossi et al., 2005).  The reason why chronic reboxetine and venlafaxine failed
to down-regulate NET or SERT but still showed antidepressant-like behavioral effects is
not known.  It is possible that differential stimulation of heteroreceptors (Chiang and
Aston-Jones, 1993; Mongeau et al., 1993), distinct interactions with P450 isoenzymes
(Cadieux, 1999; Tanaka, 1999), different binding affinities for the transporters (Lenox
and Frazer, 2002), and details regarding the nature and location of binding to the NET or
SERT (Larsen et al., 2004; Schmid et al., 2001) may account for the observed differences
among the effects of the antidepressants tested.
 Overall, the present results demonstrate a relationship between antidepressant-
induced changes in NET and SERT expression and the development of persistent
antidepressant-like effects on behavior.  Also, consistent with clinical data, it was found
that the antidepressant-like effect that resulted from SERT down-regulation depended on
the enhanced serotonergic neurotransmission, since it was lost when serotonin synthesis
was inhibited.  A similar dependence of desipramine-induced NET down-regulation on
enhanced noradrenergic neurotransmission was demonstrated previously (Zhao et al.,
2008).  The present data provide support for the idea that the down-regulation of NET
and SERT may contribute to the long-term therapeutic effects of antidepressant drugs.
The mechanism of NET and SERT regulation appears to be due more to altered
internalization and degradation than altered transcription.  Understanding the molecular
mechanisms mediating NET and SERT regulation in vivo might suggest novel targets for
therapeutic intervention in the treatment of depression.
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Antidepressants Normalized NET mRNA Normalized SERT mRNA
(mg/kg/day) level in locus ceruleus level in raphe nuclei
Protriptyline
Control 1.41 ± 0.26 N.D.
20 1.80 ± 0.33 N.D.
10 1.73 ± 0.17 N.D.
Desipramine
Control 1.59 ± 0.54 N.D.
15 2.42 ± 0.40 N.D.
Reboxetine
Control 1.08 ± 0.14 1.04 ±  0.09
20 3.14 ± 0.69*** 2.61 ± 0.73**
Sertraline
Control N.D. 1.24 ± 0.34
PCPA N.D. 0.19 ± 0.04***
7.5 N.D. 1.47 ± 0.33
PCPA+7.5 N.D. 0.42 ± 0.22***
Table 3.1 Effects of chronic antidepressant treatment on NET mRNA expression in the
locus coeruleus and SERT mRNA expression in the raphe nucleus
Rats were treated chronically with antidepressants via osmotic pumps.  NET and SERT
mRNA were determined by the real-time PCR 2 days after discontinuation of chronic
treatment (1 day post-treatment for 10 mg/kg protriptyline).  Values shown are ratios
relative to 18S rRNA (mean ± SEM; n = 5/group).  * p < 0.05, ** p < 0.01, *** p <
0.001. N.D., not determined.
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Figure 3.1   The effects of chronic protriptyline were determined for the ability to reduce
NET expression in the cerebral cortex and hippocampus, determined by 3H-nisoxetine
binding (A) and SDS-PAGE/immunoblotting (B), and to reduce immobility time in the
forced-swim test (C).  All measures were determined two days after the end of the
chronic treatment period except one group (10 mg/kg/day with 1 day washout). Data
shown are means ± SEM of 5-8 rats per group. *p < 0.05; ***p < 0.001 vs. control.
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Figure 3.2 The effect of 6-week reboxetine (20 mg/kg/day) on NET and SERT
expression in the cerebral cortex and hippocampus was determined using 3H-nisoxetine
and 3H-citalopram binding, respectively.  6-week reboxetine treatment significantly
reduced NET binding sites in both cerebral cortex and hippocampus, but not SERT
binding sites (A, B).  The NET protein expression in the cerebral cortex and hippocampus
determined by SDS-PAGE/immunoblotting with antisera against the NET was
significantly reduced only after 6-week treatment, but not after 2-week treatment (C).
The persistent antidepressant-like effect in the forced-swim test was still evident two days
after the end of the chronic treatment period (D).  Data shown are means ± SEM of 5-6
rats per group. *p < 0.05; **p < 0.01 vs. control.
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Figure 3.3   The SERT expression in the cerebral cortex and hippocampus measured by
3H-citalopram binding (A) and SDS-PAGE/immunoblotting (C) displayed significant
reduction after 2-week sertraline treatment.  The NET expression in the cerebral cortex
and hippocampus determined by 3H-nisoxetine binding (B) and SDS-
PAGE/immunoblotting (D) was not altered by chronic sertraline treatment.  To examine
whether enhanced serotonergic neurotransmission was necessary for the persistent
antidepressant-like effect in the forced-swim test, PCPA, an inhibitor of tryptophan
hydroxylase, was administered (300 mg/kg, IP) twice daily for three consecutive days
with last dose given 18 h before the forced-swim test.  PCPA reversed the sertraline-
induced antidepressant-like effect in the forced-swim test, even at a dose where it did not
affect behavior on its own (E). Data shown are means ± SEM of 5-8 rats per group. *p <
0.05; **p< 0.01; ***p < 0.001 vs. control; ##p < 0.01; ###p<0.001 vs. sertraline alone.
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Figure 3.4 The effect of 2-week of venlafaxine (70 mg/kg/day) on NET and SERT
expression in the cerebral cortex and hippocampus was determined using 3H-nisoxetine
and 3H-citalopram binding, respectively.  2-week venlafaxine treatment did not reduce
NET and SERT binding sites in both cerebral cortex and hippocampus (A, B).  The NET
and SERT protein expression in the cerebral cortex and hippocampus determined by
SDS-PAGE/immunoblotting with antisera against the NET and SERT was not changed
after chronic treatment (C, D).  However, the persistent antidepressant-like effect in the
forced-swim test was still evident two days after the end of the chronic treatment period
(D) even though neither NET nor SERT protein expression was down-regulated. Data
shown are means ± SEM of 5-6 rats per group. ***p < 0.001 vs. control.
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Figure 3.5 The NET and SERT binding sites in the cerebral cortex and hippocampus
measured by 3H-nisoxetine (A) and 3H-citalopram binding (B) didn’t change after 14-
day phenelzine treatment.  The NET and SERT protein expression in the cerebral cortex
(C) and hippocampus (D) determined by SDS-PAGE/immunoblotting displayed also no
change after 14-day phenelzine treatment.  The persistent antidepressant-like effect was
still observed in the forced-swim test 2 days after discontinuation of 14-day phenelzine
treatment (E). Data shown are means ± SEM of 5-6 rats per group. ***p < 0.001 vs.
control.
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CHAPTER FOUR
Role of PKC in NET activity in cerebral cortical
slices and antidepressant-like effects on behavior
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4.1 Abstract
The results of studies using cell culture models have suggested a role for protein kinase C
(PKC) in norepinephrine transporter (NET) regulation; experiments were carried out to
begin to assess the importance of this mechanism in brain tissue, as well to determine its
importance in mediation of antidepressant effects on behavior.  The PKC activators β-
PMA and bryostatin-1 reduced norepinephrine uptake in cortical slices in vitro; this was
due to decreased Vmax and unchanged Km values.  Reduced norepinephrine uptake also
was observed following incubation with the PP1/2A inhibitor calyculin A and the IP3
receptor antagonist 2-APB.  It also was found that i.v. or ICV administration of β-PMA
or ICV administration of bryostatin-1 produced antidepressant-like effect on forced-swim
behavior.  The effect of β-PMA on forced-swim behavior was reversed by co-
administration of 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7), a protein kinase C
inhibitor.  The present results suggest a role for PKC signaling in NET regulation in the
rat brain and indicate that modulation of PKC activity by changes in IP3 and PP1/2A
function may contribute in the mediation of antidepressant effects on behavior.  Since
NET regulation appears be involved in the development of antidepressant effects on
behavior, mechanisms involving PKC may offer novel targets for producing
antidepressant actions.
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4.2 Introduction
The NET, a target for certain antidepressants, is important in regulation of synaptic
NE concentrations; the NET mediates reuptake of NE into the presynaptic terminal,
which is the primary method of inactivation (Schomig et al., 1989).  Chronic treatment
with antidepressants that inhibit the NET, e.g. desipramine and reboxetine, down-
regulates NET expression and enhances synaptic NE levels, resulting in persistent
antidepressant behavioral effects (Zhao et al., 2008).  The time-course of down-regulation
of NET is consistent with clinical observations and provides a plausible mechanism to
explain the delayed onset of action of antidepressants in patients with major depressive
illness (Benmansour et al., 2002; Katz et al., 2004); it also is consistent with data that
suggest that enhanced monoaminergic neurotransmission is necessary for antidepressant
effectiveness (Miller et al., 1996a; Miller et al., 1996b).  The molecular mechanisms
underling chronic antidepressants-induced down-regulation of the NET, particularly in
vivo, have not been fully elucidated; however, the PKC signaling pathway does appear to
be involved (Jayanthi et al., 2004; Jayanthi et al., 2006).
The NET is phosphorylated by PKC, affecting its cellular localization and function
(Jayanthi et al., 2006). β-PMA, a PKC activator, reduces NET activity and surface
expression in HEK-293 and LLC-PK1 cells stably transfected with the human NET
(Apparsundaram et al., 1998a; Apparsundaram et al., 1998b), as well as in rat placental
trophoblasts (Jayanthi et al., 2004).  Reduced NET activity is characterized by a decrease
in the maximum transport velocity (Vmax) with little or no change in substrate affinity
(Km).  This reduction in activity is mediated primarily by the internalization of surface
NET protein (Jayanthi et al., 2004).  Site-directed mutagenesis reveals that threonine-258
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and serine-259 residues of the human NET are PKC phosphorylation sites that control
transporter internalization (Jayanthi et al., 2006).  NET activity also is reduced by the
protein phosphatase 1 and 2A (PP1/2A) inhibitors okadaic acid and calyculin A, which
prevent de-phosphorylation of the PKC sites (Bauman et al., 2000).
The PKC activator bryostatin-1 has been suggested to be a novel antidepressant,
based on preclinical data (Sun and Alkon, 2005).  Antidepressant effects caused by PKC
activation could be mediated by phosphorylation of a number of different proteins, given
the high expression of this enzyme in the brain (Saito et al., 1988).  PKC activation
facilitates synaptic neurotransmission and induces rapid morphological plasticity (Pilpel
and Segal, 2004), especially in the hippocampus, which has been implicated in
depression and its pharmacotherapy (Drevets, 2001; Liotti and Mayberg, 2001).  Some
behavioral effects of PKC activation may be mediated via the regulation of NET and
SERT cell surface expression, which has been demonstrated in vitro.  If this also occurs
in vivo, it could result in reduced monoamine transporter function and increased
monoaminergic neurotransmission (Jayanthi et al., 2005).
Most studies examining PKC-induced down-regulation of NET expression and
activity have been carried out in vitro using a variety of cell lines; it is of interest to
examine this mechanism in brain and to assess possible behavioral relevance.  The results
of the present study addressing this issue indicate that PKC activation reduces NET
activity both in vitro and in vivo and results in antidepressant-like effects in the forced-
swim test.
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4.3 Materials and Methods
Animals
Male Sprague-Dawley rats (Harlan, Indianapolis, IN), weighing 300-350g, were
housed 2 per cage in a temperature-controlled room (22 - 23°C) with a 12-h on/12-h off
light cycle (lights on at 6:00 AM).  Food and water were freely provided.  Blind
observations were used for all behavioral testing, which was carried out from 1:00 PM –
5:00 PM in a quiet room.  All procedures were reviewed and approved by the Animal
Care and Use Committee of West Virginia University Health Sciences Center, and are
consistent with the NIH “Guidelines for the Care and Use of Laboratory Animals” (NIH
publication No. 80-23, revised 1996). 
Intracerebroventricular (ICV) drug administration
ICV cannulation and drug administration were carried out as described previously
(Zhang et al., 2003).  All surgery was performed under aseptic conditions.  Rats were
anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and placed in a
stereotaxic apparatus (Stoelting, Wood Dale, IL).  Guide cannulas (22-guage; Plastics
One, Roanoke, VA) were implanted bilaterally into the lateral ventricles using the
following coordinates: AP, -0.5 mm from Bregma; ML, +1.6 mm from the midline; DV,
-3.9 mm from dura (Paxinos and Watson, 1986).  Following a recovery period of at least
one week, compounds dissolved in aCSF were injected into the lateral ventricles using a
syringe pump (1 µl over 2 min).
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Forced-swim test
The forced-swim test was carried out as described previously (Porsolt et al., 1977;
Zhang et al., 2006; Zhao et al., 2008).  Plexiglas cylinders (40 cm high and 18 cm in
diameter) were filled with water (30 cm depth, 22 – 23°C); at this depth, rats could not
touch the bottom of the cylinder with their tails or hind limbs.  On day 1, the rats were
pre-tested for 15 min to develop an immobility posture after initial escape-oriented
movements (Cryan et al., 2002).  On day 2, rats were subjected to the 5-min forced-swim
test 30 min after administration of drugs; immobility time was recorded, with immobility
defined as floating on the surface of the water with the only movement being that
required to keep the head above water.
3H-NE uptake assay
Uptake assays were carried out as described previously (Apparsundaram et al., 1998;
Vizi et al., 2004).  Fresh rat cerebral cortex was placed in ice-cold, oxygenated (95% O2 /
5% CO2), Krebs-Ringer/HEPES (KRH) buffer (125 mM NaCl, 5.2 mM KCl, 1.2 mM
CaCl2, 1.4 mM MgSO4, 1.2 mM KH2PO4, 5 mM glucose, 20 mM HEPES, 0.2 mg/ml
ascorbic acid, and 100 µM pargyline; pH 7.4).  Tissue was cut into 0.4 mm slices using a
McIlwain tissue chopper (Brinkmann, Westbury, NY).  Slices were separated by gentle
shaking and washed with oxygenated KRH buffer.  The slices were treated with β-PMA
(SigmaAldrich, St. Louis, MO) or bryostatin-1 (SigmaAldrich, St. Louis, MO) for 30 min
at 37° C.  Uptake assays were performed by incubating the tissue slices with 30 nM 3H-
NE/NE (0.03 – 3 uM; 10.9 Ci/mmol, PerkinElmer, Boston, MA) for 10 min at 37° C.
Assays were terminated by rapid washing of slices with 0.5 ml of ice-cold KRH buffer
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three times.  Buffer was aspirated and slices were then sonicated in 10% trichloroacetic
acid and centrifuged at 30,000 × g for 2 min.  3H-NE in the supernatant was quantified by
liquid scintillation counting.  Nonspecific uptake was determined in the presence of 20
µM desipramine. Specific uptake was determined by subtracting nonspecific uptake from
total uptake.
Statistical analysis
Data were analyzed by one-way analyses of variance followed by Tukey’s or
Bonferroni’s post-hoc tests.  Data are presented as means ± SEM and differences are
considered statistically significant when p values are less than 0.05.
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4.4 Results
Effects of β-PMA and bryostatin-1 on behavior in the forced-swim test
The PKC activator β-PMA (25 – 100 nmol/kg, i.v.) reduced the duration of
immobility (F(3,15)=6.86, p < 0.01; Figure 4.1A) and increased the latency to immobility
(F(3,15)=6.99, p < 0.01; Figure 4.1B) in the forced-swim test; this antidepressant-like
effect on behavior only was observed at the 100 nmol dose.  ICV administration of 20
pmol β-PMA, as well as 2 pmol bryostatin-1, another PKC activator, also reduced the
time of immobility in the forced-swim test (F(2,12)=4.58, p < 0.01; Figure 4.1C).  Co-
administration of 10 nmol H-7, a PKC inhibitor, antagonized the antidepressant-like
effects of 2 pmol, but not 20 pmol, β-PMA in the forced-swim test (F(5,18)=11.92, p <
0.001; Figure 4.1D); H-7 alone had no effect.
Effects of β-PMA and bryostatin-1 on NET activity
3H-NE uptake into cerebral cortical slices was significantly reduced after treatment
with 2 µM β-PMA in vitro (Figure 4.2A, 4.2B).  This was due to a reduction in the Vmax
from the control value of 70.0 ± 2.6 to 45.1 ± 2.5 fmol/mg protein/10min (36% reduction;
p < 0.05), with no change in the Km value (control:  0.62 ± 0.04; β-PMA:  0.53 ± 0.05
µM).  Similar effects were observed following treatment of cerebral cortical slices in
vitro with 0.5 µM bryostatin-1.  The Vmax was reduced to 49.9 ±  2.2 fmol/mg
protein/10min (29% reduction; p < 0.05), while the Km was unchanged (0.57 ± 0.04 µM).
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Effects of PP1/2A inhibitors okadaic acid and calyculin A and IP3 receptor
antagonist 2-aminoethoxydiphenyl borate (2-APB) on NET activity
Treatment of cerebral cortical slices with the PP1/2A inhibitors okadaic acid (Figure
4.4A) and calyculin A (Figure 4.4B) reduced 3H-NE uptake in vitro.  Okadaic acid
produced a near-significant effect at a concentration of 10 µM (p = 0.05), while calyculin
A was effective at concentrations at 50 µM (p < 0.05).
Treatment of cerebral cortical slices in vitro with a 50 µM concentration of the IP3
receptor antagonist 2-APB reduced 3H-NE uptake (p < 0.01; Figure 4.4C).
105
4.5 Discussion
The present findings demonstrate that PKC activators β-PMA and bryostatin-1
reduce membrane NET activity in rat cerebral cortical slices.  These data are consistent
with previous studies carried out in cell lines which show that both NET and SERT are
regulated via a PKC-dependent pathway (Apparsundaram et al., 1998b; Jayanthi et al.,
2005).  Chronic treatment with desipramine or other inhibitors of NE or 5-HT appear to
stimulate molecular factors in the PKC pathway resulting in its activation.  Activation of
PKC by β-PMA down-regulates and internalizes membrane-associated NET in cell lines
in vitro (Jayanthi et al., 2004).  The NET-PP2A-Ar complex and the NET-syntaxin 1A
complex have been shown to be involved in this process (Sung et al., 2005; Sung et al.,
2007).
β-PMA and bryostatin-1 also were found to produce antidepressant-like effects on
behavior in the forced-swim test.  Potential antidepressant-like effects of bryostatin-1
were first reported by Sun and Alkon (2005).  PKC mediation of the antidepressant-like
effects of β-PMA was confirmed by the finding that they were antagonized by the PKC
inhibitor H7.  Consistent with this interpretation, it has been reported that 4-
methylcatechol, a stimulator of brain-derived neurotrophic factor (BDNF) and an indirect
PKC activator, produces antidepressant-like effects on behavior (Sun and Alkon, 2008).
Previous work has shown that chronic treatment of rats with desipramine reduces
the expression and activity of the NET in cerebral cortex and hippocampus, resulting in
enhanced noradrenergic neurotransmission in the brain and antidepressant-like effects on
behavior (Zhao et al., 2008).  NET, as well as SERT, down-regulation has been
demonstrated following chronic treatment with a number of other antidepressant drugs.
106
The down-regulation appears to be a direct effect of antidepressant interaction with the
monoamine transporters and not secondary to increase synaptic concentrations of the
transmitters, since this effect also is observed for cell lines in vitro (Oster et al., 1989;
Zhu and Ordway, 1997; Zhu et al., 1998; Horschitz et al., 2001; Zhu, 2005; Iceta et al.,
2007).  Consistent with this, it has been found that the monoamine oxidase inhibitor
phenelzine, which increases monoaminergic neurotransmission but does not interact with
the NET or SERT, does not down regulate the transporters.  Given the role of PKC in the
control of NET and SERT trafficking and internalization, it is possible that
antidepressant-like behavioral effects of PKC activators may be mediated, at least in part,
via a reduction in cell-surface expression of the NET or SERT.
PKC isozymes, the main targets of phorbol ester tumor promoters, have important
roles in cell-cycle regulation, cell survival, malignant transformation, apoptosis, synaptic
plasticity, and neuronal injury (Griner and Kazanietz, 2007; Weinreb et al., 2004; Cejas
et al., 2005).  Three classes of PKCs (classical PKCs, novel PKCs, and atypical PKCs),
encoded by nine PKC genes, have been identified (Dekker and Parker, 1994; Hug and
Sarre, 1993; Jaken, 1996).  Classical PKCs include PKCα, PKCβI, PKCβII, and PKCγ,
which require calcium and diacylglycerol (DAG) for activation.  Novel PKCs include
PKCδ, PKCε, PKCη, and PKCθ, which require DAG.  Atypical PKCs include PKCζ and
PKCι, which require neither calcium nor DAG.  The physiological functions of the
different PKC isozymes are not known at present.
Bryostatin-1, a naturally occurring macrocyclic lacton with a chemical structure
distinct from phorbol esters, potently activates PKC but induces only part of the effects
resulting from phorbol ester treatment.   The binding of bryostatin-1 to PKC results in
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PKC activation, auto-phosphorylation, and translocation to the cell membrane.
Importantly, bryostatin-1 is ineffective as a tumor promoter (Hennings et al., 1987;
Ramsdell et al., 1986) and shows some favorable pharmacological profiles as an anti-
cancer compound (Philip and Zonder, 1999; Davidson and Haygood, 1999; Farokhzad et
al., 1998).
The involvement of PKC in the depression therapy has been implicated in several
studies and malfunction of PKC signal transduction has been suggested to be involved in
symptoms of depression (Akin et al., 2005).  The involvement of PKC in antidepressant
mechanisms also is suggested by the findings that PKC activation or phosphatase
inhibition induces phosphorylation of the NET and SERT in vitro (Ramamoorthy et al.,
1998).
It has been reported that inhibition of IP3 receptors by 2-aminoethoxydiphenyl
borate and xestospongin C reduces the Vmax of NET as well as surface NET expression in
SH-SY5Y cells (Amano et al., 2006), suggesting that the IP3 receptors/Ca
2+ system has
facilitatory effects on NET activity.  Given that activation of IP3 receptor-induced release
of Ca2+ activates PKC and consequently reduces membrane NET activity, it seems that
the regulation of the NET activity is balanced between the PLC-related signaling
pathways.  Another inducer of intracellular Ca2+ release, the ryanodine receptor, and an
influx of extracellular Ca2+ mediated by SOC channels, does not change NET activity
(Amano et al., 2006).  The changes of NET activity mediated by PKC and IP3 receptors
have been only demonstrated in cell lines in vitro.  A demonstration of the importance of
this mechanism in vivo might suggest a novel mechanism to produce NET (or SERT)
down-regulation with resulting antidepressant-like effects on behavior.  The activation of
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PKC signaling pathway by chronic antidepressant treatment might provide a mechanism
underlying neuroadaptive changes in NET and SERT function.
Overall, the present study demonstrates a relationship between PKC activation-
induced antidepressant-like effect in the forced-swim test and PKC activation-induced
reduction of membrane NET activity in the rat cerebral cortical slices.  This suggests the
importance of future experiments to examine the means by which antidepressants alter
PKC activity to affect cell surface expression of monoamine transporters and to identity
molecular targets in this pathway that might provide a novel means for producing
antidepressant effects on behavior.
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Figure 4.1 The PKC activator β-PMA produced antidepressant-like effects on forced-
swim behavior.  This effect was observed 3 h after i.v. administration of β-PMA, as
indicated by reduced immobility time (A) and increased latency to immobility (B).
Bilateral ICV administration of 20 pmol β-PMA and 2 pmol bryostatin-1, another PKC
activator, 30 min before testing reduced also immobility time in the forced-swim test (C).
Bilateral ICV administration of the PKC inhibitor H-7 (20 nmol) reversed the
antidepressant-like effect of 2 pmol PMA in the forced-swim test  (D).  Data shown are
means ± SEM for 5 – 6 rats per group. *p < 0.05, **p < 0.01 vs. vehicle; ##p < 0.01 vs. 2
pmol PMA alone.
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Figure 4.2 The PKC activator β-PMA reduced NET activity in cerebral cortical slices in
vitro; this was due to a reduction of the Vmax and an unchanged Km value.  The NET
activity was determined after incubation with 4 concentrations of [3H]NE.  Data shown
are means ± SEM of 5 – 6 rats per group. *p < 0.05, ***p < 0.001 vs. control.
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Figure 4.3 The PKC activator bryostatin-1 reduced NET activity in cerebral cortical
slices; this was due to a reduction of Vmax and an unchanged Km value.  The NET activity
was determined after incubation with 4 concentrations of [3H]NE/NE.  Data shown are
means ± SEM of 5 – 6 rats per group. *p < 0.05, ***p < 0.001 vs. control.
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Figure 4.4 The PP1/2A inhibitors okadaic acid and calyculin A reduced NET activity in
rat cerebral cortical slices, as evidenced by a reduction in the uptake of [3H]NE.  The IP3
receptor antagonist 2-APB also reduced NET activity.  Data shown are means ± SEM of
5 – 6 rats per group. *p < 0.05, **p < 0.01 vs. control
117
Conclusions
The present study demonstrates a relatonship between antidepressant-induced down-
regulation of the NET and antidepressant-like effects on behavior.  This relationship also
is observed for the SERT.  The down-regulation of the transporters and long-term
antidepressant-like behavioral effects are evidient two days following discontinuation of
chronic treatment, when acute drug effects are minimized.  Consitent with clinical
findings, the antidepressant-like effect in the forced-swim test is reversed by inhibiton of
NE or 5-HT neurotransmission, suggesting that the enhanced NE and serotonin
neurontransmission is necessary, but not sufficient, to produce antidepressant-like effects
on behavior.  The mechanism of NET and SERT regulation by antidepressants likely is
more due to altered transporter protein internalization than altered gene transcription.
Further, PKC activators show some antidepressant-like effects in the forced-swim test
and this is accompanied by reduced membrane NET activity in rat cerebral cortical slices.
This suggests a possible PKC signaling pathway mediating NET regulation in vivo and
that may be associated with antidepressant effects.  Understanding molecular events that
regulate NET and SERT in vivo may suggest pharmacological targets for the
development of novel antidepressant drugs.
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